Design: Tissue microarrays (TMAs) were constructed from genetically profiled tumors (3 TMAs, n = 149), of which 34 have TP53 mutations and 20 have RB1 mutations or deletion. We performed immunohistochemistry for p53 and RB on all TMA slides as well as on full sections form another set of tumors with TP53 (n = 10) and RB (n = 14) mutations. These full sections contained both invasive and non-invasive UC to compare the expression patterns between these 2 components. Results: From the TMAs, in 34 tumors with known TP53 mutation, p53 expression was strong and diffuse in 19 (19/34), was completely negative in 10 cases (10/34), and focally/weakly positive in 5. In 20 tumors with known RB1 mutation, RB expression was completely lost in 17 cases (17/20), and focally/weakly positive in 3 cases. Cases that were TP53/RB1 wild type exhibited a spectrum of expression but generally none were diffusely and strongly positive for p53 or completely negative for RB. RB expression was lost in both the invasive and non-invasive components in all RB1 mutated tumors (adjacent normal urothelium and stromal cells retained RB expression). Similarly, in TP53 mutated tumors, the patterns of expression were similar between the invasive and non-invasive components. Conclusions: Although TP53 mutations are well-known to be early events in UC, we demonstrate that RB1 loss is an early event in the development of urothelial carcinoma. RB1 mutations result in complete loss of RB expression in overwhelming majority of the cases. TP53 mutations may result in either diffuse and strong p53 expression or, less frequently, complete loss of expression. Awareness of these patterns of expression may be helpful in assessing the potential role of these markers in patient risk stratification. Design: 42 cases of GS7 PCa were studied. H&E sections were reviewed to confirm the diagnosis. Representative tumor areas were microdisected. DNA was extracted from the paraffin sections. DNA library was prepared with PCR amplification. Each patient sample was barcoded and loaded for emulsion PCR for clonal amplification. The amplified DNA copies were then sequenced on the Ion torrent PGM. The sequences were analyzed with variant caller software. 19 genes that have been repeatedly shown to be mutated in PCa ("prostate genes" including APC, AR, FAT3, FOXA1, KLK2 ,KLK3, KLK4, MED12, MUC16, MUC2, MUC4, SCN11A, SPOP, THSD7B, TNXB, TP53, TTN, ZAN and ZNF595) and Ion Torrent HotSpot Cancer panel that contained genes frequently altered in other cancers were sequenced. FISH on paraffin-embedded tumor tissue was performed using commercially available DNA probes for PTEN, ERG, and PIK3CA. Results: Using FISH to detect ERG/TMPRSS2 translocation and PTEN deletion, 12 (30%), 29 (71%), 7 (18%) and 7 (18%) tumors had alteration involving ERG, PTEN, both genes and none of the genes. One of 37 tumors had PIK3CA amplification while none had AR amplification. None of these changes correlated with PSA recurrence. Using NGS to sequence the "prostate genes", 16 mutations were detected in 15 of 42 tumors, averaging 0.4 mutation per tumor. These mutations involved SPOP gene in 6 tumors, TP53 in 4, MED1 in 2, FoxA1 in 2, AR in 1and ZAN in 1. One tumor had two mutations, 14 had 1 mutation and remaining 27 had no mutations. Mutations in SPOP correlated marginally with PSA recurrence with PSA recurrence in 0 of 6 tumors with SPOP mutation and in 12 of 31 (39%) tumors with wild type SPOP (p=0.064). Mutation in KIT was detected in 8/43 (19%) tumors. KIT mutation occurred only in PTEN deleted tumors (7/22, 32%), but not in PTEN wild type tumor (0/12, p=0.062). Conclusions: Gene mutations are rare in GS 7 PCa. SPOP is mutated in 6/42 (15%) of tumors and marginally correlates with PSA recurrence. Chromosomal alterations involving PTEN and ERG are much more frequent. Relationship between PTEN deletion and KIT mutation warrants further investigation.
Diagnosis
Total n n positive % positive n strong diffuse protein 78 (GRP78), an endoplasmic reticular (ER) chaperon protein, increases with chronic stress and may lead to malignant transformation after translocating to the nucleus from the ER. GRP78 is immunosuppressive although its mechanism is not known. GRP78 may enhance expression of immune response gene 1 (IRG1) to suppress antitumor immunity. Metformin, an anti-diabetic drug, has been suggested to have antitumor effect. The goal of this study was to examine whether GRP78 is associated with enhanced expression of immunosuppressive IRG1 and whether metformin treatment suppresses IRG1 expression in OVCA patients. Design: Experiment-1: GRP78 expression and its association with ovarian epithelial malignant transformation was examined in archived ovarian specimen from subjects with (n=10) or without (n=10) OVCA risk including BRCA mutations. Experiment-2: Specimens from OVCA patients treated with (n=20, serous) or without metformin (early stage, n=5 for each of the serous, endometrioid, mucinous and clear cell; and late stage, n=10, serous) were used. Effects of metformin treatment on GRP78 and IRG1 expression were determined and compared by paired T-tests and oneway ANOVA.
Results: Ovarian and fimbrial surface epithelial cells in subjects with OVCA risk showed strong GRP78 expression. Compared with OVCA without metformin treatment, the intensity of GRP78 expression decreased remarkably in metformin-treated OVCA patients (P<0.01). Similarly, malignant cells in OVCA without metformin showed strong IRG1 expression while it was weak or absent in metformin treated patients (P<0.001). GRP78 was positively correlated with IRG1 expression.
Conclusions:
The results of this study suggest that expression of GRP78, a molecular marker of cellular stress, is associated with OVCA development and suppression of anti-tumor immunity. Metformin treatment reduces immunosuppression by decreasing GRP78 possibly by reducing cellular stress. This study will lead to a larger study to develop anti-tumor immunotherapies. Support: Swim Across America. Kristen M Basnet, Rhonda Bentley-Lewis, Deborah Wexler, Fusun Kilic, Drucilla Roberts. Massachusetts General Hospital, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR. Background: Intervillous thrombi (IVT) are common placental pathologies of unclear etiology. Intervillous thrombi may form as a protective reaction against fetomaternal hemorrhage in the setting of villous trophoblastic membrane disruption. One possible cause for trophoblastic disruption is apoptosis, and a role for hyperglycemia in trophoblast apoptosis and placental dysfunction has been suggested. We sought to determine if placentas from pregnancies complicated with diabetes had an increased incidence of IVT. Design: Medical records of 206 obstetric patients at the Massachusetts General Hospital with well characterized diabetes: Type I diabetes (n=39), Type II diabetes (n=37), and gestational diabetes (GDM, n=130) , from 1994 to 2011, were identified. Placental pathology reports were reviewed to determine numbers of IVT in each group. For patients with placental IVT, gestational and maternal age-matched controls were selected from the pathology archives comprising placentas examined only for the indication of Group B Streptococcus positivity. Control patient medical records and placental pathology reports were then reviewed to confirm euglycemia and identify the presence of IVT, respectively. Fisher exact test was used for statistical analysis.
Intervillous Thrombi Are Increased in Placentas from Pregnancies Complicated by Diabetes
Results: An increased incidence of IVT was present in patients with diabetes as a group (Type I, Type II, and GDM; 32/206, 15.5%; p = 0.04) and in GDM exclusively (22/130, 16.9% ; p = 0.03) versus controls (7/99, 7.1%). IVT were also increased in patients with Type I diabetes (4/39, 10.3%) and Type II diabetes (6/37, 16.2%) compared to controls (7/99, 7.1%), but the results did not attain statistical significance (p = 0.73 and 0.19, respectively).
Conclusions:
The incidence of IVT is increased in the placentas of patients with diabetes as a group (Type I, Type II, and GDM), and in patients with GDM in particular, versus those of euglycemic patients. This is the first report of an association between diabetes and an increased incidence of placental IVT. Our findings give support to the hypothesis that trophoblastic apoptosis associated with diabetes may be the etiology of the increased incidence of IVT. Dina Bassiouny, Nadia Ismiil, Matthew Cesari, Valerie Dube, Guangming Han, Fang-I Lu, Elzbieta Slodkowska, Hak Fai Chiu, Nim Li, Magda Naeim, Mahmoud Khalifa, Sharon Nofech-Mozes . Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Background: Histopathologic evaluation of HE slides is usually sufficient for cell typing in most cases of ovarian carcinomas and immunohistochemistry (IHC) is used as an adjunct diagnostic tool in difficult cases. Recent reports highlighted Hepatocyte Nuclear Factor β (HNF-1β) as a sensitive marker in ovarian clear cell carcinoma (OCC). Its expression in ovarian serous and endometrioid adenocarcinoma is significantly lower. Current data is limited with regards to HNF-1β expression in ovarian mucinous carcinoma (OMC). Design: HNF-1β expression was studied by IHC (Sigma, Aldrich CA, 1:200) on 41 OMC arrayed in 1mm duplicate cores. Cases were identified through the Biomatrix institutional research database. IHC was scored semiquantitatively; % positive nuclei: 0 (< 1%), 1-25% (1+), 25-50% (2+), 50-75% (3+), >75% (4+); intensity: weak (1+), moderate (2+), strong (3+). Each core was scored individually and the highest score was considered for interpretation. Results: Tissue was available in 40/41 cases. There was a high level of concordance among paired cores. HNF-1β was positive in 37/40 (92.5%) cases, 34 cases showed strong and diffuse nuclear positivity (score ≥ 6; Figure 1 ), whereas 3 cases showed moderate staining (score 4-5). Conclusions: HNF-1β is diffusely expressed in the majority of OMC and is not specific for OCC. Since clear cell changes may be encountered in other cell types, in challenging cases, HNF-1β should be used in a panel and the interpretation should be made with caution in the context of tumor morphology.
HNF1-β Is Strongly Expressed in Ovarian Mucinous Carcinoma

MMR Protein Expression in Ovarian Carcinoma: A Clinicopathologic Study
Dina Bassiouny, Sharon Nofech-Mozes, Nadia Ismiil, Matthew Cesari, Valerie Dube, Guangming Han, Elzbieta Slodkowska, Hak Fai Chiu, Eugene Hsieh, Nim Li, Magda Naeim, Mahmoud Khalifa, Fang-I Lu . Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Background: Lynch syndrome (LS) accounts for 10 to 15% of all inherited ovarian cancer cases. Deficient MMR expression can be used for its screening. The aim of this study is to evaluate MMR protein expression in ovarian carcinomas (OC). Design: All H/E slides were reviewed with a gynecologic pathologist to confirm diagnosis. MMR protein expression was evaluated in 608 OC accessioned between 2000-2013, arrayed in 1 millimeter cores in duplicates and characterized by immunohistochemistry (IHC). MLH1, MSH2, MSH6 and PMS2 were assessed as intact or deficient. The latter required a positive internal control. Equivocal cases were confirmed on full slides. The clinicopathologic characteristics were compared between the groups using χ2 test and t-test. Results: Nine/608 patients (1.5%) demonstrated deficient MMR expression. One/ 9 patients (11.1%) had concurrent loss of both MSH2/MSH6, 4 (44.4%) had combined loss of MLH1/PMS2, 3 (33.3%) had only MLH1 loss and 1 patient (11.1%) had only loss of PMS2. Two patients with combined loss of MLH1/PMS2 had personal or family history of other malignancies which raises the possibility of LS. Deficient MMR tumors were high grade, 5 endometrioid and 4 serous (p=0.001). They were more likely to be unilateral (p=0.05) and presented at early stage (66.7% at I/II) (p=0.003) and frequently associated with ovarian or extra-ovarian endometriosis (p=0.05). Age, surface involvement, tumor lymphocytic infiltrate, lymphovascular invasion or disease free survival between groups were not significantly different.
Conclusions:
High grade OC of serous and endometrioid subtypes that are unilateral and are associated with endometriosis are more likely to be MMR deficient. Tools to efficiently select and screen patients with OC at risk for LS are needed.
TLR4 and MAD2: Drivers of Chemoresistance in Ovarian Cancer
Mark Bates, Luke Gubbins, Dorinda Mullen, Eimear Lee, Jacqui Barry-O'Crowley, Danielle Costigan, Ciaran O'Riain, Cathy D Spillane, Michael F Gallagher, Cara Martin, Amanda McCann, Sharon O'Toole, John J O'Leary Background: MAD2 is a key protein involved in the spindle assembly checkpoint and knockdown of this protein has been shown to facilitate paclitaxel resistance through the induction of senescence. Additionally low MAD2 immunohistochemical (IHC) staining has been associated with reduced progression free survival (PFS). Conversely the TLR4-MyD88 pathway is known to mediate paclitaxel resistance through the upregulation of pro-tumourigenic cytokines and pro-survival genes and blockage of this pathway has been shown to restore chemosenstivity to paclitaxel. Furthermore high TLR4 IHC staining is associated with reduced PFS. Design: A2780 and SKOV-3 cells were transfected with siRNA targeting MAD2. MAD2 and TLR4 expression was then analysed by RT-PCR. SKOV-3 cells were subsequently transfected with siRNA targeting MAD2 and then treated with 1µM paclitaxel. Cell viability was then assessed using the CCK-8 assay. β-galactosidase activity was also measured in SKOV-3 cells following transfection using the Senescence β-Galactosidase Staining kit. Results: In this study a novel link between TLR4 and MAD2 was observed. Specifically when MAD2 was knocked down in both A2780 and SKOV-3 cells, a 3 fold upregulation of TLR4 mRNA expression was observed. MAD2 knockdown in SKOV-3 cells was also shown to render SKOV-3 cells highly resistant to paclitaxel. These cells displayed enlarged cell and nuclear size and an increase in β-galactosidase activity. Additionally TLR4 and MAD2 expression was analysed by IHC in a tissue microarray cohort of high grade serous, stage 2-4 ovarian cancer patients (n=36). Patients with a TLR4 high and MAD2 low phenotype had significantly reduced DFI (p=0.002) and PFS (p=0.002), compared to those possessing any other phenotype, a reduction in patient overall survival was also observed but this was just below significance (p=0.081).
Conclusions:
The results demonstrate the development of a lethal phenotype which is highly resistant to paclitaxel chemotherapy and a synergy between the MAD2 senescence Conclusions: Introduction of a standardized protocol led to a statistically significant increase in the number of identified lymph nodes. Increased lymph node counts did not result in a detectable improvement in the detection of patients with metastatic disease. The protocol had the advantage of standardizing expectations between surgeons and pathologists, thereby reducing uncertainty. Lymph node counts are currently being evaluated as a possible quality parameter within surgical treatment of endometrial carcinoma, and thus a standardized method of processing lymph nodes is essential. The proposed protocol may serve as a model for processing of lymphadenectomy specimens.
Do Antibody Clones of PD-L1 and PD-1 Expressing Tumor Infiltrating Lymphocytes in Cervical Tumors Matter?
Luis F Carrillo, Peter N Bonneau, Alexander C Mackinnon, Irene Aguilera-Barrantes. Medical College of Wisconsin, Milwaukee, WI. Background: PD-L1 expression and PD-1 positive tumor infiltrating lymphocytes (TILs) have been associated with various solid tumors. Therapies developed against PD-L1 have been suggested to show strong anti-tumor response, suggesting potential clinical utility for these markers. To date, few studies have examined the expression of PD-L1 and PD-1 positive TILs within cervical tumors, and none comparing available antibody clones. The objective of this study was to evaluate cervical tumor for expression of PD-L1 and PD-1 positive TILs using different antibody clones for each marker. Design: A tissue microarray was constructed with 27 cervical tumors. IHC for PDL-1 (Cell Signaling, E1L3N; Spring BioScience, SP142) and PD-1 (Abcam, NAT105; Biocare, NAT105) were performed on all cervical tumors. Any cytoplasmic or membranous staining was recorded as positive for both PD-L1 and PD-1, with a case considered positive for PD-1 with the finding of any positive TILs. Positive TILs were counted within a single 400x high-power field (HPF), using a hot-spot approach.
Results: PD-L1 tumor positivity and PD-1 positive TILs were observed frequently in both squamous cell carcinomas and cervical adenocarcinomas. There was no significant difference observed between staining for either PD-L1 clone or PD-1 manufacturers. Staining for PD-L1 was often only weak and focal. Conclusions: PD-L1 and PD-1 positive TILs are often associated with cervical tumors, with positivity found in nearly all squamous cell carcinomas tested. The antibody clone or manufacturer used does not significantly affect positivity.
PAX-8 immunoexpression was seen in 4 patients (24%; 3 patients with diffuse and strong staining, 1 patient patchy and strong staining). All 4 patients underwent surgery for non-neoplastic conditions (2 patients with endometriosis, 1 with appendicitis, 1 with ruptured ectopic pregnancy). In 1 case, the morphology of the mesothelial proliferation was distinctly papillary. D2-40 and calretinin immunostains were strongly positive in all cases. Conclusions: Although PAX-8 expression was seen in a minority of cases, when positive it can be diffuse and strong. While PAX-8 immunohistochemistry can be a diagnostic aid in morphologically challenging cases, a panel of immunostains should be employed as PAX-8 staining can occur in reactive mesothelial proliferations. Daniel Carvajal-Hausdorf, Kurt Schalper, Yalai Bai, Jonathan Black, Alessandro D Santin, David L Rimm. Yale University School of Medicine, New Haven, CT. Background: HER2 overexpression/amplification is identified in up to 40% of uterine serous (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents have failed to show significant responses. FDAapproved HER2 assays target only the protein's intracellular domain (ICD) and not the extracellular domain (ECD) . Previous quantitative studies in breast cancer by our group have shown that the ICD of HER2 is expressed in some cases that do not express the HER2 ECD. We measured HER2 ICD and ECD in USC and OSC samples, and determined their relationship with clinico-pathologic characteristics and survival. Design: We measured HER2 ICD and ECD levels in 2 cohorts of USC and OSC comprising 102 and 175 patients, respectively. HER2 antibodies targeting ICD (CB11) and ECD (SP3) were validated and standardized using the AQUAⓇ method of quantitative immunofluorescence (QIF) and a previously reported HER2 standardization tissue microarray (TMA). Median cut-point was used to stratify patients according to HER2 ICD/ECD status. Results: In USC, 32% of patients with high HER2 ICD had low ECD levels (16/50 patients). HER2 ECD was associated with younger age (P=0.007). HER2 ICD and ECD levels were not associated with survival. In OSC, 39% of patients with high HER2 ICD had low ECD levels (34/87 patients). There was no association of HER2 ICD/ECD status with age and staging. HER2 ICD-high status was significantly associated with longer disease-specific survival (DSS) (log-rank P=0.019, HR=0.53, 95% CI: 0.32-0.90). HER2 ECD was not associated with survival. HER2 ICD-high status was independent predictor of better outcome in a Cox proportional hazards model including age and stage. Conclusions: Using objective, domain-specific HER2 measurement, approximately one third of USC and OSC patients with high HER2 ICD levels do not show uniform overexpression of the ECD. This may be related to the presence of p95 HER2, an oncogenic fragment generated by full protein cleavage or alternative initiation of translation. These observations raise the possibility that USC/OSCs that express low ECD despite gene amplification (and HER2 positivity by ICD-targeted antibodies) may benefit less from therapies that target the extracellular domain (e.g. trastuzumab) and more from kinase inhibitors (e.g. lapatinib or afatinib) that target the intracellular domain.
Objective, Domain-Specific HER2 Measurement in Uterine and Ovarian Serous Carcinomas and Its Clinical Significance
Cytological Recognition of Serous Tubal Intraepithelial Carcinoma from Tubal Cytology and and Pelvic Washing Samples
Hao Chen, Robert R Klein, Stacy J Arnold, Li Li, Setsuko K Chambers, F Zahra Aly, Wenxin Zheng. University of Arizona, Tucson, AZ. Background: High-grade serous carcinoma (HGSC) is a significant cause of mortality in women mainly due to advanced stage of presentation. The secretory cells within the epithelium lining the fallopian tube have been proposed as the cell of origin for the majority of ovarian HGSC. The earliest recognized histologic precursor lesion of HGSC is serous tubal intraepithelial carcinoma (STIC). In our previous study, we characterized the distinct cytological features of malignant fallopian tube epithelium.
In the current study, we attempt to test the sensitivity of detecting HGSC and STIC using the same established cytological criteria of fallopian tube sampling. Finally, we explore the usage of the biomarkers IMP3 and P53 in detection of STIC and HGSC in pelvic washings specimen. Design: A total of 56 tubal specimens collected from 38 patients who underwent bilateral salpingo-oophorectomy (BSO) due to various indications including pelvic mass suspicious for malignancy, benign disorders, and prophylactic BSO. A standard procedure using cytobrush to collect epithelial cells from tubal fimbria is performed as previously described. The fallopian tube was then entirely submitted for histological examination. Correlation between tubal cytology and histological findings of the tube or pelvic washings was performed. IHC staing for IMP3 and p53 was performed when cytologic atypia was seen. Results: Diagnoses from tubal brushings divided into 3 categories and the number of each category are recorded as follows: benign (n=36), atypical (n=7)and a combined suspicious and confirmed malignancy (n=11). The cytological diagnosis of malignant or suspicious for malignancy is highly correlated with the histological finding of HGSC (100%). Interestingly, two malignant cytology specimens showed no invasive cancers within the fallopian tube. However, STIC was found. Cytological evaluation of pelvic washing is positive in 7 of 9 patients with histological diagnosis of HGSC. IMP3 and p53 immunostaining of pelvic staining highlight malignant cell clusters and intraepithelial neoplasm. Both IMP3 and p53 staining are negative in atypical cell clusters.
Conclusions:
The cytological approach by obtaining tubal epithelial cells has potential to be a useful method for ovarian cancer screening and early detection. Fallopian tube cytology is more sensitive in detecting HGSC and STIC than pelvic washing cytology. IMP3 and p53 immunostaining is helpful in detecting intraepithelial neoplasm in pelvic washing specimen. Wenqian Chen, Arjumand Husain, Gregg Nelson, Peter Rambau, Sandra Lee, Maire Duggan, Cheng-Han Lee, Martin Kobel. University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Center, Calgary, AB, Canada; University of Alberta, Edmonton, AB, Canada; Chinook Regional Hospital, Lethbridge, AB, Canada. Background: Endometrial serous carcinoma (ESC) is an aggressive neoplasm occurring in older women. The objective of this study is to i) to refine immunohistochemical (IHC) panels to encompass differential diagnoses endometrioid grade 3 (EC3) and clear cell carcinomas (CCC) ; ii) to explore, which biomarker differentiates it from ovarian high-grade serous carcinomas (HGSC); and iii) to explore whether IHC expression as a surrogate for molecular alterations is a prognostic factor. Design: 52 ESC from a single institution were assessed for 16 IHC markers, including ARID1A, CCNE1, ER, HNF1B, FBXW7, IGF2BP3, NAPSA, CDKN2A, TP53, PAX8, PGR, PTEN, TFF3, VIM and WT1. ERBB2 chromogenic in situ hybridization (CISH) was evaluated on tissue microarrays. Statistics analysis was performed.
Immunohistochemical Profiling of Endometrial Serous Carcinoma
Results: All ESC showed aberrant TP53, normal mismatch repair protein, retained ARID1A and PTEN expression. A panel of TP53, PTEN and CDKN2A had a sensitivity of 93.6% (95% CI, 84-98%) and specificity of 87.8% (95% CI, 75-95%) for ESC versus EC3, a panel of NAPSA and ER had a sensitivity of 97.9% (95% CI, 89-99%) and specificity of 72.2% (95% CI, 46-90%) for ESC versus CCC, and WT1 alone had a sensitivity of 66.0% (95% CI, 51-79%) and specificity of 98.0% (95% CI, 94-99%) for ESC versus HGSC. Among all 52 ESCs, ERBB2 amplification was present in 23%, FBXW7 expression was absent in 10%, and CCNE1 was overexpressed in 59%. However, none of those was associated with prognosis.
Conclusions: This study demonstrated ubiquitous aberrant TP53 expression, absence of PTEN, preserved mismatch repair protein expression, ARID1A abnormalities, and high expression levels of ER in ESC. This will support the value of IHC marker panels for histotyping of high grade endometrial carcinomas.
ES/PNET, A Potential for Misdiagnosis: Clinicopathologic and Molecular Cytogenetic Analysis of 5 Cases with Literature Review
Yufan Cheng, Rui Bi, Bin Chang, Wentao Yang, Xiaoyu Tu, Jian Wang. Fudan University Shanghai Cancer Center, Shanghai, China. Background: Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) constitute a family of neoplasms characterized by a continuum of neuroectodermal differentiation.
The most common primary site of involvement is along the central axis, particularly the chest (Askin tumor). ES/PNET of the genital tract is very rare, especially of uterine corpus and cervix, always presenting a diagnostic challenge. We describe 5 cases here, with the emphasis on the clinicopathologic and molecular cytogenetic features. Design: We describe 5 cases here, with the emphasis on their clinicopathologic and molecular cytogenetic features.
Results:
The patients ranged in age from 13 to 42 years (average 28 years). Lower abdominal pain and abnormal uterine bleeding were the most common symptoms. 3 cases located in cervix. 2 cases arised in uterine corpus, with one of them involving pelvic organs. 4 patients underwent total abdominal hysterectomy and bilateral salpingooophorectomy and, in one patient, pelvic lymphadenectomy. 1 patient accepted a submucosal tumor resection. Histologically the tumor was composed of uniform, rounded, oval and sometimes spindle shaped cells with a narrow rim of eosinophilic cytoplasm. Slim fibrous septa were occasionally seen between the tumor cell nests. In one case, neoplastic cells focally formed neuroectodermal rosettes. Mitoses and coagulative necrosis were easily found. By immunohistochemical studies, the tumor cells of all of the 5 cases were positive for CD99, Vimentin, negative for P63, Desmin, HMB45 and CD10. 4 of them were positive for cytokeratin (AE1/AE3) and synaptophysin. It was noted that most of the cases presented definitely AE1/AE3 immunostain and in one of them, P16 positive stain was also identified, resulting in a diagnostic confusion with small cell carcinoma. In all of the 5 cases, molecular testing demonstrated the rearrangement of EWSR1 gene, which confirmed the diagnosis of ES/PNET. Conclusions: As small cell carcinoma (SCC) is more frequently seen in uterine cervix and corpus, the overlapping features between ES/PNET and SCC may lead to a misdiagnosis. Therefore, a timely confirmation with molecular analysis is essential for the diagnosis.
Overdiagnosis of HSIL (CIN 2): Four Nonspecific p16 Immunohistochemistry Patterns
Jennifer L Clark, Yuxin Liu. University of Massachusetts Medical School, Worcester, MA.
Background:
The LAST project recommends p16-IHC to classify putative CIN2 into LSIL or HSIL. HSIL is supported by strong, diffuse, "block-like" p16 staining pattern.
Our aim was to assess the impact of implementing p16-IHC and various clinical outcomes of this emerging group, "p16-classified HSIL." Design: We searched the UMass database for patients fulfilling the criteria: HSIL diagnosis on biopsy, p16-IHC performed, and two-year surveillance. Medical charts were reviewed. Results: Among 210 eligible patients, HSIL was present in 136 (65%) subsequent LEEPs and absent in 74 (35%). These 74 patients underwent surveillance for two years, revealing no high-grade lesions. On review of these 74 cases, 42 (57%) showed concurrence, while 32 (43%) were downgraded to LSIL based on morphology and nonspecific p16 staining. Table 1 shows the clinicopathological characteristics of these 32 patients whose p16-IHC revealed 4 nonspecific patterns (Table 2, Figure 1 ): thin basal (n=13;41%), patchy (n=12;37%), minute fragment (n=5;16%), and mosaic (n=2;6%). and partial mole (PM), is a non-neoplastic proliferative disorder of the placental villi and may develop into gestational trophoblastic neoplasia (GTN). Most studies of the incidence of HMD have relied upon morphologic diagnosis and were conducted before both the routine use of obstetrical ultrasound (ObU/S) to detect abnormalities and the medical management of spontaneous and missed abortions. Our retrospective institution-based study aimed to re-assess the incidence of HMD and the CM: PM ratio when the diagnosis of HMD is made by histopathology with the selective use of p57 immunohistochemistry (IHC) and molecular genotyping (MG). Design: Consecutive hospital cases of HMD and number of deliveries were identified over a 27 month period. A diagnosis of CM required the typical histopathologic appearance for CM alone, or atypical villous morphology (AVM) with absent IHC villous staining. A diagnosis of PM required the typical appearance for PM, or AVM suspicious for PM and MG findings of diandric triploidy or triploidy. MG analysis determining parental contribution was performed on microdissected formalin fixed paraffin embedded sections of maternal and conceptus tissues using QF-PCR analysis of 19 polymorphic short tandem repeat markers. Results: Forty-nine HMD cases were identified: 18 CMs and 31 PMs. IHC confirmed the diagnosis in 17/18 CM's. No MG was performed in the CMs. MG was performed in 24/31 PMs since histopathology was equivocal; diandric triploidy was identified in 21 cases and triploidy in 3 cases. The average number of monthly deliveries was 558.
If the expected incidence of HMD in North America is between 1.0 and 2.0 per 1000 deliveries is assumed to represent a normally distributed 1-sigma confidence interval, our observed HMD incidence (3.1 /1000) is significantly greater than this expected incidence (p < 0.001).
Conclusions:
The true incidence of HMD may be higher than has been appreciated previously. This finding is likely attributable to increased detection of placental abnormalities by ObU/S and the ability of MG to definitively identify PM in cases which are equivocal by histopathology alone. The CM: PM ratio of 18/31 approaches 1:2, and could provide a useful laboratory benchmark. Some GTN cases with an apparent history of abortion only could be attributable to undetected HMD. The hematoxylin and eosin (H&E) stained sections from cases that identified SCC on excision but made no mention of LS in the original pathology report were reviewed by an expert gynecologic pathologist (MS). These cases were reviewed for evidence of LS that was not originally reported. Patients who had LS identified in the original pathology report were recorded as such, and the slides for these cases were not reviewed. The grade of the excised SCC was also recorded for all patients in our study population.
Results:
The proportion of our study population patients with synchronous LS and vulvar SCC upon excision was 0.29 with 95% confidence interval limits of 0.21 -0.38. There were 9 patients in our study population who did not have LS identified adjacent to the vulvar SCC on excision, but who did have a previous histopathologic diagnosis of vulvar LS. Using this information, the proportion of patients in our study population who have ever had a histopathologic diagnosis of LS is 0.36 with a 95% confidence interval of 0.28 -0.45. Thus, 36% of patients who underwent excision for invasive SCC during our study period had a histopathologic diagnosis of LS at one point in their lives. The presence of LS on the excision specimens was not associated with the grade of the adjacent SCC. Conclusions: Our study is the largest to date to report the prevalence of LS in vulvar SCC excision specimens. Based on the 36% association of LS with vulvar SCC found in our study, we recommend that pathologists and clinicians carefully evaluate and report the presence of LS given its association with differentiated VIN and invasive SCC. Background: A Chemotherapy Response Score (CRS) system was recently described to assess the histopathologic response and prognosis of patients with HGSC receiving neoadjuvant chemotherapy (NACT). The current study was performed as an independent assessment of the CRS system. Design: Cases included 72 patients with stage III-IV HGSC who underwent interval debulking procedures after NACT. One H&E slide of omental (n=68) and/or adnexal (n=61) tumor showing the least treatment effect (selected by one pathologist) were included (n=57 with both omentum and adnexal slides available). All slides were independently scored by 11 pathologists (2 trainees, 2 junior gynecologic pathologists, and 7 senior gynecologic pathologists) from 2 institutions using only the published description of the three-tiered CRS system (Table 1) . Interobserver variability was assessed utilizing Fleiss' kappa (κ). Patients were stratified according to consensus CRS. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and were compared using the log-rank test.
The overall interobserver reproducibility was good for omentum (κ 0.64) and moderate for adnexa (κ 0.52). There was no difference between CRS1 and CRS2 for OS and PFS (p>0.05) however, for omental disease, CRS1/2 were associated with a median PFS of 11 months (95%CI 9-14) vs. 22 months (95%CI 18-27) for CRS3 (p=0.006). An omental score of CRS3 demonstrated a trend toward prolonged median OS, but this was not statistically significant (54 months (95%CI 31-76) for CRS3 vs. 37 months for CRS1/2 (95%CI 25-48) (p=0.083)).
Conclusions:
The CRS system reported by Böhm et al. appears to offer a relatively reproducible method for predicting PFS, with the favorable prognostic factor being CRS3. Additional web-based training on specific CRS criteria may improve interobserver reproducibility and prognostic value.
Criteria for the Chemotherapy Response Score
CRS1
No or minimal tumor reponse. Conclusions: For the first time, we document the expression of GREB1 in the spectrum of POMNs and tumors of upper and lower GI origin. The combination of positive GREB1 and/or PAX8 is highly sensitive for tumors of ovarian origin. Thus, GREB1 can be a useful tool in the diagnostic work-up of mucinous tumors involving the ovary. Design: 13 sections diagnosed independently as IEA-A by three gynecologic pathologists, and 14 sections of benign endocervix (BE) with tunnel clusters, diffuse laminar hyperplasia or normal architecture were selected. Three additional pathologists evaluated a digital image from each section and classified it as IEA-A or BE based on the architecture only. To blind the interpretation to cytologic features, nuclei and cytoplasm were obscured using morphometric software (Zen 2011, Carl Zeiss Microscopy, Germany) . Results: 13/27 cases (48%, 8 IEA-A and 5 BE) were correctly classified by all three reviewers; 19/27 (70%, 10 IEA-A and 9 BE) were correctly classified by at least two reviewers. 3/13 IEA-A cases (23%) were interpreted as BE by at least two reviewers. Conversely, 5/14 BE cases (36%) were interpreted as IEA-A by at least two reviewers.
CRS2
Conclusions: An abnormal architecture, distinct from BE patterns, is seen in many IEAAs supporting their dessignation as invasive lesions. However, some cases interpreted as IEA-A have architecture that overlaps with that of BE, thus may represent AIS. In addition, BE can be architecturally complex and mirror patterns that pathologists would classify as IEA-A if malignant cytologic features were present. Given this overlap and the nil risk of nodal spread of IEA-A, the term "endocervical adenocarcinoma with nondestructive proliferation" can be considered when applying the PBC.
Adenocarcinoma, diagnosed as IEA-A by 3 pathologists (A). Once cytologic details were obscured (B), 3 separate reviewers classified it as BE. In contrast, a case of BE (C) was misdiagnosed as IEA-A by 2/3 reviewers when blinded to cytologic features (D). Background: Our objective was to determine, in the setting of surgical staging for endometrial cancer (EC): 1)whether processing the additional adipose tissue that remains after gross identification of lymph node (LN) candidates results in the identification of additional LNs; and 2)whether division of LN tissue into nodal basin-specific specimens has any effect on the number of LNs identified. Design: Following IRB approval and informed consent, a prospectively accrued randomized controlled trial was performed of women with high-grade EC who were scheduled for surgical staging. At surgery, subjects were randomized to collection of LNs into nodal basin-specific containers (e.g., left external iliac, left common iliac) on the randomized side versus simple labeling (right pelvic and right aortic) on the nonrandomized side. The total number of LNs and total number of LNs with metastases on the randomized versus the non-randomized side were compared using a one-sided paired t-test. The remaining adipose tissue from each LN specimen was submitted for histologic examination in addition to all grossly identified LN candidates. We analyzed the number of LNs and the number of LNs with metastatic carcinoma identified from the additional adipose tissue. Results: Of the 120 patients that gave consent, 62 had sufficient tissue and data to be included in this analysis. The additional adipose tissue contained 7.2 additional LNs per patient on average (range, 0-26). In 3/62 total cases (5%) and 3/17 cases with LN metastases (18%), the additional adipose tissue contained LNs with metastatic carcinoma. In all three cases, metastatic disease was also detected in ≥1 grossly identified LN candidate. The mean number of LNs identified was not significantly different based on method of specimen collection/submission: 11.1 (randomized side) versus 10.5 (non-randomized side) (p=.24, n=52). Likewise, the mean number of LNs containing metastatic disease per side was not significantly different: 0.31 (randomized) versus 0.37 (non-randomized) (p=.58). Conclusions: LN totals are higher when all of the tissue in LN specimens is examined microscopically. The presence of LNs with metastases in the additional adipose tissue is important because the number of positive LNs has prognostic significance. These findings suggest that submitting all adipose tissue from LN specimens for EC should be considered. Mohamed El Hag, Tracy A Stein, Bo Ye, Prachi Raut, Haodong Xu, Mahmoud Khalifa, Faqian Li. University of Minnesota Medical Center, Minneapolis, MN; UCLA Medical Center, Los Angeles, CA. Background: SOX17 is a member of the Sry-related HMG box transcription factor family which play key roles in embryogenesis and development. Expression of SOX17 is regulated through the Wnt/β-catenin signaling pathway. RT-PCR has shown SOX17 expression in tissues including testis and ovary. However, the utility of SOX17 as a diagnostic/prognostic marker has not been investigated in endometrial adenocarcinoma (EAC). The purpose of this study is to evaluate SOX17 expression patterns in EAC and to determine its prognostic significance, in addition to investigating its relationship with β-catenin. Design: TMA of 41 endometrial cases (36 EAC and 5 benign endometria) was stained for initial evaluation of SOX17 expression. Subsequently, whole slides from 20 cases representing 12 patients (11 primary EACs and 9 metastatic EACs) were reviewed and stained for SOX17 and β-catenin. The presence and intensity of SOX17 nuclear expression was graded from 0 to 3 and percentage of tumor cells in each grade was estimated. A total SOX17 intensity score was calculated and used to compare primary versus metastatic disease. Additionally, β-catenin intensity and localization was documented.
SOX17 Is Highly Expressed in Endometrial Adenocarcinoma
Results: SOX17 was positive in 76% of TMA cases (31/41). All benign endometrium TMA specimens stained intensely (3+). 72% of EAC TMA specimens were positive (26/36). Interestingly, all whole slide EAC cases (20/20) stained positively for SOX17, but showed inter-and intra-specimen variation in intensity and percentage of tumor cell positivity, reflecting tumor heterogeneity. Cases of primary EAC had an average SOX17 intensity score of 155.46 and median of 160, compared to metastatic EAC (average 210/median 230). Β-catenin showed nuclear positivity in 47% of EAC cases, predominantly in areas of squamous differentiation which were negative for SOX17, in contrast to surrounding SOX17-positive adenocarcinoma. Conclusions: SOX17 is variably but consistently expressed in EAC. An opposite staining pattern of SOX17 and β-catenin is observed in EAC: β-catenin predominantly highlights squamous differentiation while SOX17 decorates glandular components. Additionally, an increased number of positive tumor cells and increased SOX17 intensity was observed in metastatic disease. However, only 11 primary EAC cases were analyzed, precluding correlation of SOX17 expression with FIGO grade and tumor stage. Further investigation is underway to confirm SOX17 expression in primary versus metastatic disease, as well as the value of SOX17 expression in tumor grading and prognostication. Background: Twin pregnancies with a normal placenta and complete mole (CM) have a higher risk of persistent trophoblastic disease than conventional CM, and should be differentiated from its mimics, such as partial mole (PM) and CM with mosaicism, for patient management. Design: Nine cases of morphologically twin pregnancy with CM in the first trimester and three cases of clinically putative twin pregnancy with CM were investigated by immunostaining of p57 (Kip2) (p57) and TSSC3, which are products of paternallyimprinted, maternally-expressed genes. DNA ploidy was also analyzed by flow cytometry in three cases, all of which were diploid. One case was chromosomally analyzed. Results: Patient ages ranged from 20-38 years (mean, 32 years), and gestation ranged from 8 to 12 weeks (mean, 8.5 weeks). Clinically, hydatidiform mole was suspected in nine cases, and abortion or blighted ovum was suspected in three cases. The initial pathologic diagnosis was PM in nine cases and CM in three cases. On review, six cases were histologically diagnosed as CM with twins (twin pregnancy with a coexisting normal placenta and CM). The admixture of large hydropic villi with circumscribed trophoblastic hyperplasia and smaller, normal-appearing villi without trophoblastic hyperplasia was observed in all cases. The cytotrophoblasts and stromal cells in the larger villi were negative for p57 (androgenic) and TSCC3, whereas these cells were positive in the smaller villi (biparental) in six cases. Three cases were conventional CM and two cases were CM with foci of placental mesenchymal dysplasia. Immunohistochemically, all tumors were positive for CAM5.2, CD10, and calretinin, and negative for ER, PgR, and CEA. Of the 11 patients with follow-up information available (mean, 60 months), 3 patients with MMMT (2 in the meso-ovary or ovary, 1 in the uterine body) died of the disease at 25, 51, and 100 months, respectively, after surgery. No patients with AC and follow-up information died of disease. One patient was alive with lung metastases and the remaining 9 patients had no evidence of disease 6 to 76 months postoperatively. Conclusions: A diversity of histologic patterns was observed, with 9 cases arising from outside the uterine cervix, and mesonephric remnants or hyperplasia were found in only 5 cases. Because two cases exhibited mixed epithelial elements and one was associated with endometriosis, some MMTs without mesonephric remnants may be identified as adenocarcinomas with mesonephric differentiation. The possibility of a mesonephric tumor should be considered when encountering an unusual-appearing carcinoma, malignant mixed tumor, or even an endometrioid adenocarcinoma. All of the patients with AC and follow-up information survived. In contrast, 3 of the 4 patients with MMMT died of disease. MMMTs may be more aggressive than ACs. Conclusions: Molecular classification of ECs can be achieved using clinically applicable methods on formalin-fixed paraffin-embedded samples, and provides independent prognostic information beyond established risk factors. This pragmatic molecular classification tool has potential to be used routinely in guiding treatment for individuals with endometrial carcinoma and in stratifying cases in future clinical trials. Conclusions: This study provides further evidence that MELF has a predominant EMT-like mesenchymal phenotype. Although an M phenotype is associated with worse prognosis in other cancers (pancreatic and colonic) when not present at the invasive front but expressed in the main tumor, limited data from our pilot study shows that a conspicuous M signature in MELF does not negatively impact prognosis of EEC.
CyclinE1 Expression in High Grade Serous Carcinomas and Malignant Mixed Mullerian Tumors
Joseph Hatem, Carolina Reyes. Hospital of the University of Pennsylvania, Philadelphia, PA. Background: Amplification of Cyclin E1 gene (CCNE1) has been found in a subset of ovarian high grade serous carcinomas, which in association with cyclin-dependent kinase 2 (CDK2), activates the cell cycle. Amplification of CCNE1 is associated with resistance to platinum-based therapy and overall worse disease-free and overall survival. Pharmacologic agents that target CDK2 are in development and may be effective in the treatment of CCNE1 amplified HGSC. CCNE1 amplification has also been found in other neoplasms. Malignant mixed Mullerian tumors (MMMT) of the uterus are rare and little is known about the molecular pathogenesis of this tumor. Preliminary work on few cases has suggested that Cyclin E1 may be overexpressed in a subset of MMMTs. We evaluated the expression of Cyclin E1 by immunohistochemistry (IHC) on cases of HGSC and MMMT. In doing so, we aimed to support the existing literature regarding overexpression of Cyclin E1 in HGSC. In addition, we sought to evaluate for overexpression in MMMTs. Design: Paraffin blocks form 28 cases of HGSC and 25 cases of MMMTs were retrieved. Unstained sections were stained with an antibody to Cyclin E1. Positive and negative controls were reviewed and found to be adequate. Cyclin E1 expression was scored on a 4-point scale (0 to 3+).
Results: All cases of HGSC showed at least weak expression of Cyclin E1. Strong (3+) expression was seen in 57% of HGSC. 25% showed moderate (2+) expression and 18% showed weak (1+) staining. Both the carcinoma and sarcoma components of the MMMT cases were assessed for Cyclin E1 expression. Regarding the carcinoma component, strong expression was seen in 24% of cases. 38% showed moderate expression, 24% showed weak expression, and 14% were negative. Regarding the sarcoma component, strong expression was seen in 17% of cases, 13% showed moderate expression, 45% showed weak expression and 25% were negative. Conclusions: Our findings support existing literature of Cyclin E1 overexpression in a large subset of HGSC. We also expand upon the existing evidence by demonstrating the expression pattern of Cyclin E1 in a large subset of MMMTs. The findings are important in light of recent efforts to develop cyclin-dependent kinase 2 (CDK2) inhibitors.
Rethinking Decidual Vasculopathy of Preeclampsia
Jonathan H Hecht, Zsuzsanna K Zsengeller, Ananth Karumanchi, Seymour Rosen. Beth-Israel Deaconess Medical Center, Boston, MA. Background: Preeclampsia is associated with a failure of arteriolar transformation by trophoblastic colonization resulting in decidual vasculopathy (DV). While this vascular transformation has been extensively studied in the placental bed, there is limited data on the morphologically similar vascular injury in decidual vessels of the free membranes. Design: We describe DV in the membranes using stains for CD31, CD34, Cd42b, CD68, desmin, fibrin and Masson's trichrome in patients with preeclampsia. Membrane-roll sections from the placentas of 6 patients with preeclampsia were examined. Results: DV was detected in 34-80% of small arteries per case with 302 vessels examined. Changes ranged from so called hypertrophic DV with medial hypertrophy, to more dilated vessels with fibrinoid necrosis / atherosis. Affected vessels showed endothelial proliferation with detachment. Remodeling of the media was characterized by smooth muscle loss and fragmentation with variable degrees of fibrin deposition. CD31 and CD34 highlighted the prominent endothelium and showed striking particulate staining throughout the media (Fig. 1 ). CD42b (platelet marker) staining in these vessels was minimal. Detection of nitrotyrosine in the intima and media was noted and suggested reactive nitrogen species generation / oxidant injury. Conclusions: All of these findings infer a sequence of endothelial injury, fragmentation and repair with incorporation of endothelial components into the vascular wall. This kind of rampant endothelial injury seems to be a characteristic finding in the placenta of preeclampsia and may be responsible for the elevated circulating endothelial microparticles that some have found in patients with preeclampsia. 
Utility of Immunolabeling with Stathmin-1 in the Accurate Classification of Anal Squamous Intraepithelial Lesions
Erika Hissong, Adela Cimic, Edyta C Pirog. Weill Cornell Medical College, New York, NY. Background: The classification of anal intraepithelial neoplasia (AIN) in mucosal biopsies is subject to considerable inter-observer variability, yet the distinction between low and high grade lesions is clinically important in determining potential therapeutic options and the need for continued surveillance. Because of this diagnostic dilemma, a search for objective immunohistochemical markers that may aid in the diagnosis of equivocal cases has been undertaken. Stathmin-1 is a microtubule-destabilizing protein shown to be important during mitosis. In normal squamous mucosa it is expressed exclusively in the basal cells. The aim of this study is to determine whether immunohistochemistry for Stathmin-1 enhances diagnostic accuracy in the assessment of anal mucosa biopsies. Design: This is a retrospective pilot study of 39 anal biopsies and includes the normal anal transitional zone (NL, n=10), low-grade AIN (AIN1, n=10), and high-grade AIN (AIN2, n=9, AIN3, n=10). The histologic features of all cases were re-reviewed and agreed upon by two independent pathologists. The mean age at the time of diagnosis was 47. Twenty-seven (27) patients were male and twelve (12) patients were female. Immunohistochemistry for Stathmin-1 was performed and staining patterns (lower third of the epithelium, lower two thirds and full thickness) together with intensity of staining (1-3+) were evaluated. The staining was considered positive if at least two thirds of the epithelial thickness was immunoreactive (1-3+).
Results: There was no positivity for Stathmin-1 in NL and AIN-1. Interestingly, 62% of AIN 2 lesions fulfilled the criteria for the positive staining by strong (2-3+) positivity in lower two thirds but no full thickness staining was detected. 88% of AIN3 lesions were positive, of which 66% showed full thickness staining.
Conclusions:
In the subset of high grade intraepithelial lesions, Stathmin-1 showed greater sensitivity for AIN3 than AIN2 (sensitivity = 55% for AIN2, 80% for AIN3). AIN2 lesions are commonly the most difficult to classify. In the difficult cases when morphology is not sufficient and immunohistochemistry is warranted for the diagnosis, Stathmin-1 alone may not be sufficiently sensitive for a reliable diagnosis of high grade intraepithelial neoplasia. However, in our study, immunohistochemistry for Stathmin-1 shows excellent negative predictive value in normal epithelium or AIN1 lesions (NPV=76%), in contrast to known data. Lien Hoang, Mary A Kinloch, Katherine Grondin, Cheng-Han Lee, Carol Ewanowich, Martin Kobel, David G Huntsman, Jessica N McAlpine, Robert Soslow, Blake We performed molecular analysis on a series of endometrial carcinomas and stratified them into the same molecular groups as modeled by the Cancer Genome Atlas (TCGA) (Br J Cancer 2015; 113:299-310) . Using this series, we examined interobserver histologic agreement within each of the 4 molecularly defined groups. The goal was to determine which group is most challenging to diagnose using standard histologic assessment. Design: Seven gynecologic subspecialty pathologists based in different tertiary care centers assigned histologically-based diagnosis given 151 endometrial carcinomas using 1-2 representative slides from hysterectomy specimens. Inter-observer agreement in histotype diagnosis was then compared between each of the 4 TCGA groups.
Inter-Observer Agreement in Endometrial Carcinoma (EC) Diagnosis Varies Depending on TCGA Subgroup Assignment
Results: Inter-observer agreement in each of the 4 TCGA groups is summarized in In this study, we compare the ability of endometrial biopsies (EMB) to predict the final classification made on hysterectomies (Hyst), using both techniques, histopathologic assignment and molecular analysis. Design: 51 EMB and corresponding Hyst were selected from institutional archives. Sequencing for POLE, TP53 and immunohistochemical evaluation of DNA mismatch repair proteins were performed independently in both the EMB and Hyst, and used to stratify each into 1 of the 4 TCGA molecular categories (MSI, POLE, CN-L, CN-H), as described previously (Br J Cancer 2015; 113:299-310) . 3 gynecologic subspecialty pathologists also assigned histotype diagnoses. Diagnoses made on the original pathology report (by mostly non-specialized pathologists) were also analyzed. Results: TCGA group assignment using EMB reliably predicted group assignment in Hyst (kappa = 0.85; excellent agreement) ( Table 1) . Gynecologic subspecialty pathologists frequently predicted Hyst final diagnosis (average kappa = 0.69; substantial agreement), but original EMB pathology reports were less successful (kappa = 0.35; fair agreement). Conclusions: Molecular classification of endometrial carcinomas made on EMB and Hyst have excellent concordance and can serve as an alternative or adjunctive classification strategy for endometrial carcinomas. Classification using histologic diagnosis was overall moderate; gynecologic subspecialty pathologists more frequently predicted final diagnosis compared to non-specialized pathologists. Conclusions: For the first time, we demonstrate expression of GREB1 across the most common ovarian carcinoma histotypes. Unlike in breast cancer, GREB1 expression does not correlate with ESR1 expression in ovarian cancer. The frequent GREB1 expression may represent activation of estrogenic pathways that are independent of ESR1, and suggests that GREB1 may be a more sensitive marker of estrogen-related activity than ESR1. As such, GREB1 may be a useful and a more robust alternative biomarker to ESR1, both in the diagnostic setting and for assessment of eligibility for adjuvant hormonal therapies.
Novel Marker GREB1 Is Frequently Expressed in -Major
Proteomic Profiles of Vulvar Squamous Cell Carcinoma
Emily Holthoff, Stephanie Byrum, Thomas J Kelly, Alan Tackett, Steven Post, Charles Quick. UAMS, Little Rock, AR. Background: Vulvar squamous cell carcinoma (vSCC) is a gynecologic malignancy diagnosed in nearly 4500 women in the US each year. High risk of recurrence and nodal metastasis lead to increased morbidity and mortality in these patients. In previous studies, we identified 2 major variants of vSCC. Some tumors exhibit a pushing invasive pattern and lymphoplasmacytic (LPC) stromal response; others display an infiltrative invasive pattern and a fibromyxoid (FMX) stromal response. We also showed that infiltrative tumors with FMX stroma are more likely to recur and metastasize to the lymph nodes, exhibit perineural invasion, and undergo an epithelial mesenchymal transition (EMT). Molecular tumor features that contribute to these outcomes have not been well defined in vSCC and may be due to differential expression of key proteins involved in biological processes that aid in tumor growth and invasion. Design: In this study, label-free high resolution LC-MS/MS was used to determine the proteomic profiles of FFPE tissue sections from 10 infiltrative vSCC with FMX stroma and 10 pushing vSCC with LPC stroma. Of these 20 tumors, 11 were associated with recurrence and 8 contained lymph node metastases. Proteomic profiles were associated with morphologic tumor features, tumor recurrence, and nodal metastases to identify proteins linked to increased risk of adverse outcomes. Results: When comparing infiltrative and pushing tumors, 205 proteins exhibited significant expression changes between the two groups. Importantly, 42 proteins were uniquely identified in infiltrative tumors. Included in these was thrombospondin-4, a glycoprotein that mediates cell-matrix interactions and may play a role in macrophage recruitment. In addition, 96 proteins were identified only in the pushing tumors, including STAT1, which may play a significant role in mediating effects of the inflammatory stromal response through IFNγ signaling. Expression of 105 proteins was either significantly different or uniquely identified in recurrent tumors, and the expression of 115 proteins was either uniquely identified or significantly varied in tumors with nodal metastases. Included in these 115 significant proteins was SRPX2, an important regulator of FAK signaling and cell motility, which could contribute to increased metastatic potential in these tumors. Conclusions: Overall, our results identify a proteomic profile in vSCC that implicates a role for specific pathways in differentiating aggressive vulvar squamous cell carcinoma as defined by morphologic tumor features, recurrence, and nodal metastases. Background: A subset of tumors expresses the PD-1 ligands to engage PD-1 on T-cells and inhibit anti-tumor immunity. Clinical responses to PD-1 blockade are associated with PD-L1 expression by tumor cells and provide a rationale for screening tumors to identify patients most likely to benefit. However, the biological basis for expression of PD-L1 is poorly understood. In this study we investigate expression of PD-L1 using immunohistochemistry (IHC) and correlate with genetic alterations using fluorescence in situ hybridization (FISH). Design: In a series of cervical (n=48) and vulvar (n=23) SCCs, we performed FISH on formalin-fixed, paraffin-embedded tissue (FFPE) with probes targeting CD274 (PD-L1), PDCD1LG2 (PD-L2), and the centromeric region of chromosome 9 (control). A minimum of 50 malignant cells were scored to determine the target:control ratio. A target:control ratio of >3:1 were scored as amplified, <3:1 but >1:1 as co-gain, and 1:1 as polysomy (if >2 copies), disomy (if =2 copies), or monosomy (if <2 copies). IHC using mouse anti-human PD-L1 monoclonal antibody (clone 9A11) was performed and evaluated for percentage of tumor with positive staining (0-100%) and average intensity of staining (0=negative, 1=weak, 2=moderate, 3=strong) without knowledge of the genetic status of the tumors. A modified H-score was generated by multiplying percentage and the average intensity of positive staining (0-300).
Results:
In cervical SCC, co-amplification or co-gain of CD274 and PDCD1LG2 was present in the majority of cases (32/48; 67%). PD-L1 expression across tumors demonstrated a range of H-scores (0-270) that was highest among co-amplified cases and lowest among disomic cases (p =0.0013). In vulvar SCCs, 6/23 (26%) had co-amplification and 4/23 (17%) had co-gain of CD274 and PDCD1GL2. PD-L1 IHC revealed a correlation of higher PD-L1 expression with increasing copy number gains (p=0.0021). Conclusions: Our data reveal that selective copy number gain of CD274 and PDCD1LG2 at 9p24.1 occurs frequently in SCCs of the cervix and vulva and provides a genetic basis for increased PD-L1 protein expression, potentially aiding in immune evasion. Patients whose tumors have a genetic basis for PD-1 ligand expression may be uniquely sensitive to PD-1 blockade. LGSCs and M-SBTs using immunohistochemical markers to provide possible clues to the similar biologic behavior of M-SBT and LGSC. Design: Forty-nine tissue samples including 9 M-SBTs, 21
LGSCs, 16 epithelial implants and 3 proliferative endosalpingiosis from 34 patients were retrieved. H&E slides were reviewed to confirm the diagnosis and presence of lesional areas.
Immunohistochemistry for membranous markers E-cadherin and p120 was performed and read by two pathologists to see alteration of staining patterns to identify reversal of cell polarity. Results: Membranous staining was robust for both markers in all cases. E-cadherin and p120 staining showed unique staining patterns similar to what has been described in invasive micropapillary breast tumors as indicating cell polarity reversal: absent immunostaining on the peripheral border of papillary clusters and staining of the basal and lateral aspects of the cells. Staining patterns in LGSC (figure 1) and M-SBT (figure 2) differed from benign lesions, e.g., proliferative endosalpingiosis and Implants which did not show alteration of staining patterns.
Conclusions: Patterns of immunostaining of E-cadherin and p120 are similar in
LGSCs and M-SBTs indicating reversal of cell polarity. In contrast, loss of cell polarity was not observed in benign lesions. This finding supports the view that LGSC and M-SBT may have similar biologic potential and may be related lesions. 2 were 3 and 24/10 HPF, respectively. Using ROC analysis, a PHH3 score of ≥6/10 HPF was highly compatible with malignancy with sensitivity of 80.6%, specificity of 93.7%, and positive and negative predictive values of 92.5% and 83.3%, respectively. For malignant USMT, multivariate analysis showed that a PHH3 score of ≥29/10 HPFs was independently associated with a poor outcome.
Conclusions:
In USMT with ambiguous morphologies, a PHH3 score of ≥6/10 HPF is highly predictive of malignancy. PHH3 score may also be a useful prognostic indicator for malignant USMT. However, a non-molar pregnancy established using a donor egg will also show a genotype that does not match the recipient maternal decidua, potentially causing misinterpretation as a dispermic CHM. Since a donor egg pregnancy has a biparental genome, most STR loci should show heterozygous alleles but in a dispermic CHM, which is uniparental, most loci should be homozygous. In a monospermic CHM, all of the STR loci should be homozygous, so misinterpretation is unlikely. We propose that evaluating the pattern of STR allele zygosity can distinguish the genotype of donor egg products of conception (POC) from dispermic CHM. Design: STR genotype (AmpFISTR Identifier PCR Amplification system targeting 15 STR loci) and p57 immunostaining of 10 donor egg POC (6 with abnormal morphology suspicious for CHM) was compared to 22 CHM (2 dispermic). The ratio of allele zygosity (homozygous versus heterozygous) at the STR loci was compared. Data was interpreted blinded to whether a donor egg was used. Results: All 10 donor egg POC resembled the genotype of CHM in that all showed genotypes that did not match the maternal decidua. However, most STR loci had heterozygous alleles in donor egg POC whereas most were homozygous in dispermic CHM (p<0.0001). Positive p57 staining in villous cytotrophoblast and mesenchyme confirmed biparental genome in all 10 donor egg POC while all CHM lacked p57 staining as expected.
Allele Zygosity Donor Egg POC Dispermic CHM
Homozygous loci 26% 76%
Heterozygous loci 74% 23%
Ratio of Heterozygous to Homozygous loci 3:1 1:3
Conclusions: Evaluation of the ratio of heterozygous to homozygous loci is essential before interpreting a DNA genotype as a CHM. If the ratio is high (3:1 or more), the possibility of a donor egg pregnancy should be considered and p57 immunohistochemistry should be performed. In this setting, positive p57 staining confirms a donor egg was used and excludes a CHM. From a practical standpoint, it may be prudent to use p57 staining to confirm any diagnosis of dispermic CHM based on DNA genotyping alone. The most common histologic findings in cases of elastosis were flattened rete pegs and dermal homogenization; elastic stain shows both increased density and abnormal distribution of elastic fibers in the papillary and reticular dermis.
Cases of LS were characterized by dermal homogenization, flattened rete pegs and hyperkeratosis. On elastic stain, these cases uniformly showed abnormal loss of elastic fibers in the papillary dermis.
None of these features were present in the normal controls. Conclusions: These findings confirm that elastosis is a histologic mimic of LS and should be considered in the differential diagnosis. Background: Pregnancies that implant in the uterine cornua (cornual pregnancy) or intra-myometrial (interstitial) portion of the fallopian tube (interstitial pregnancy) carry a higher risk of morbidity than conventional ectopic tubal pregnancy due to extra risk of rupture of uterine wall blood vessels. Management may include salpingectomy along with cornual resection, even though the extra-uterine fallopian tube is not abnormal. This may cause diagnostic confusion in evaluating these specimens, particularly since clinicians may refer to these as "ectopic pregnancies" and since the pathology of cornual/ interstitial pregnancy is not well described in the literature. Design: 15 patients in our archives were suspected to have cornual pregnancy and underwent management resulting in a pathologic specimen. Slides were reviewed to map the anatomic location of chorionic villi and placental implantation and to define the incidence of salpingitis isthmica nodosum (SIN), tubal endometriosis, and chronic salpingitis. Background: Implementation of HPV detection by means of molecular genetics has improved efficiency of cervical cancer screening in terms of increased sensitivity. The inadequate specificity of an HPV test for identifying only severe precancerous lesions is solved by colposcopy and/or histological examination of tissue-biopsies. Additional biomarkers analysed from liquid-based cytological (LBC) samples could better define the real risk of HPV positive patients of having a high-grade lesion and decrease the number of patients who have to undergo an invasive diagnostic procedure. In our study, we focused on molecular genetic analyses of two aspects potentially reflecting higher risk of disease progression: (1) HPV-driven methylation silencing of selected tumour-suppressor genes and (2) the presence of selected infectious agents discussed as possible transforming cofactors. Design: 51 paired samples of LBC and consecutive punch or cone biopsy of the cervix rendering the diagnosis of HSIL within 6 weeks interval had been prospectively identified. Analysis of methylation silencing of tumour-suppressor genes CADM1, MAL, and has-miR-124, related to cervical carcinogenesis, was performed in LBC samples using methylation-specific qPCR. Furthermore, these samples were investigated for the presence of selected human herpesviruses -HSV1, HSV2, VZV, EBV, CMV, HHV6, HHV8; polyomaviruses -BK, JC, Merkel cell polyomavirus (MCPyV); and Chlamydia trachomatis, using PCR methodology, and compared to LBC cervical smears of 51 women without HPV infection.
Results: Methylation silencing of selected tumour-suppressor genes was detected in 26 patients (58 %), 19 patients were negative for methylation, and 6 samples were not suitable for analysis due to their low cellularity. The most commonly detected infectious agent in the study group was MCPyV (6 cases), followed by EBV, JCV, and Chlamydia trachomatis (4 cases each). CMV, HSV1, and HHV6 were detected in one case each.
Conclusions:
The positive methylation status of tumour-suppressor genes CADM1, MAL, and has-miR-124 detected in LBC smear holds promise in identifying HPVpositive patients at higher risk for disease progression. Several infectious agents were detected in the study samples, but this finding was not statistically significant though we have to consider the bias of small study group. and IL-6 (138 cases) were performed. Complete lack of nuclear immunoreactivity of the cells was considered loss of BAF250a expression. IL-6 expression was scored using: 0 = negative, 1-50% = focal, and > 50% = diffuse. Progression-free survival (PFS) and overall survival (OS) were calculated, and comparisons were made using the log-rank test. 
Adenosquamous Carcinoma and Adenosquamous Intraepithelial Lesion of the Cervix: Analysis of a Rigorously Classified Case Series
Michael Keeney, Gary L Keeney, John Schoolmeester. Mayo Clinic, Rochester, MN. Background: Adenosquamous carcinoma (ASC) of the uterine cervix is an ill defined neoplasm subject to misclassification. We thoroughly evaluated cases coded as ASC from our institutional archive to better describe its clinical and pathologic features. Design: Case inclusion criteria were threefold: 1.The specimen was processed at our institution 2.The specimen was a hysterectomy or trachelectomy 3.A singular invasive neoplasm demonstrate morphologic and immunophenotypic evidence of squamous (keratinization, intercellular bridges or other such features) and glandular (cuboidal to columnar epithelium in circinate or tubular structures) differentiation. Cases were identified using keywords "ASC" and "cervix." Immunohistochemical stains (p63,p40,p16,ER,PR) and in-situ hybridization for human papillomavirus E6/E7 RNA (HPV ISH) were performed. Clinical data were retrieved from the medical record.
Results: Thirty-two cases met criterion #1. Fifteen cases were excluded due to failure of criterion #2 or slides were not available. Seventeen cases were then histologically evaluated and eleven (73%) were reclassified as an assortment of entities. Four cases (27%) met all 3 inclusion criteria and were striking in their morphologic heterogeneity. More, these cases featured a distinctive intraepithelial lesion with both squamous(p63+) and glandular(p63-) differentiation ( Conclusions: ASC is an uncommon, heterogenous neoplasm with a distinctive intraepithelial lesion we term "adenosquamous intraepithelial lesion." Although historically considered a neoplasm with a poorer outcome by some studies, from our limited, but rigorously classified series, patients may present at advanced stage yet may have similar outcomes to other HPV-associated cervical carcinomas.
Clinical Outcomes in a Subset of Endometrial Surface Epithelial Lesions with Marked Nuclear Atypia
Elizabeth Kehr, Marisa R Nucci, Christopher P Crum. Brigham and Women's Hospital, Boston, MA. Background: Uterine serous carcinoma has been associated with a precursor termed serous endometrial intraepithelial carcinoma (SEIC). SEIC has been shown to have metastatic potential with a recurrence risk approaching 5%. Thus, its proper recognition in curettings is vital to ensuring early and effective treatment. Diagnostic features of SEIC include an abnormal surface or superficial glandular epithelial proliferation with elevated N/C ratio, loss of polarity and both strong p53 (or complete loss) staining and elevated MIB1 index. Nevertheless, there is a subset of surface endometrial epithelial lesions with marked nuclear atypia (EMATYP) that may be difficult to distinguish from SEIC. This study addressed a series of EMATYPs seen in a consultation practice. Design: The consultation files were scanned for cases classified as p53 positive EMATYP. Histologic features, p53 and MIB1 immunohistochemistry were recorded. Followup information from subsequent histologic samples were obtained.
Results: A total of 18 EMATYPs were retrieved betweem 2006-2015. In 8 a SEIC was diagnosed. In 10, a diagnosis of EMATYP was made. In the latter, the most consistent histologic features were conspicuous nuclear enlargement and variable N/C ratio accompanied by strong p53 (or null) immunostaining. MIB1 proliferation indices varied, ranging from 10-40%. One case was strongly positive for p16. All 8 cases classified as SEICs had followup hysterectomy procedures with the following results: one invasive serous carcinoma, 6 SEIC, and one had atypia of unclear significance. Conversely, the 10 cases of EMATYP had followup hysterectomy procedures with the following results: three had diagnoses of SEIC (including the p16+ case); two had diagnoses of endometrioid intraepithelial neoplasia, two had diagnoses of atypia of unclear significance; and three had negative hysterectomies.
Conclusions: EMATYP appears to be a distinct subset of p53-positive atypias seen in postmenopausal women with a significant risk of neoplasia and an estimated risk of SEIC to be 30%. The finding of marked surface endometrial intraepithelial atypia is a significant finding. It underscores the importance of follow up in cases when some, but not all, features of SEIC are encountered. Moreover, nuclear enlargement, a feature often associated with reactive atypias, does not exclude the possibility of a serous neoplasm, particularly in the setting of strong p53 staining. The use of additional markers (such as p16), should also be considered when triaging these p53 positive atypias. Background: Recently, TERT promoter mutations have been identified in urothelial carcinoma (UC) with high frequency, and some studies suggest that they may serve as a biomarker for aggressive disease. As benign Brenner tumors of the ovary show urothelial differentiation, both histologically and immunophenotypically, we had previously investigated TERT promoter mutations in a series of these tumors and found none of them to have these mutations. Since TERT promoter mutations are found to be present in UC and are absent in benign urothelium, we investigated a series of malignant Brenner tumors of the ovary in order to determine their TERT promoter mutation status. Design: One of our databases was searched for malignant Brenner tumors and 5 cases were identified, all of which were consultation cases. These cases were re-reviewed, and unstained slides from selected tissue blocks were obtainable from 4 of these cases for genomic DNA extraction. Macrodissection was used in some cases to ensure that 20% of the cells were neoplastic. TERT promoter mutations were detected by standard PCR-sequencing.
Results:
In the 4 cases of malignant Brenner tumors with available material, the mean age of the women at diagnosis was 66 (range 53-76). All cases showed the characteristic features of malignant Brenner tumors, showing either thick, blunt, elongated papillae lined by malignant transitional-type epithelium exhibiting cystic and/or solid growth patterns and areas of stromal invasion, or a disorderly, angulated growth pattern of epithelial nests with an invasive appearance in a tumor with solid growth. High grade cytologic atypia resembling that seen in high grade UC was present in all cases. Importantly, all cases showed an associated benign or atypical proliferative Brenner component, distinguishing these tumors from solid serous carcinomas with a transitional cell component or metastatic UC from the urinary tract. TERT promoter mutations were detected in none of the 4 cases (0/4).
Conclusions:
In conjunction with our prior study on a series of benign Brenner tumors which also showed an absence of TERT promoter mutations, the current study further suggests that despite the morphologic resemblance to high grade UC of the urinary tract, malignant Brenner tumors may exhibit a molecularly distinct pathogenesis. Although malignant Brenner tumors are exceedingly rare, these findings may have therapeutic implications since the molecular pathogenesis of these tumors appears to be different from typical high grade UC. LGLS-EEC). Exon 3 mutations prevent phosphorylation of β-catenin, promoting nuclear translocation and subsequent activation of the Wnt/β-catenin signaling pathway. Cyclin D1 is characteristically upregulated by this pathway. The goal of this study was to determine if β-catenin and/or cyclin D1 immunohistochemistry (IHC) could be used as a surrogate to CTNNB1 gene sequencing and hence as a screening tool in the management of women with LGLS-EEC. Design: Tumors from 51 patients with advanced/recurrent endometrial carcinomas were subjected to a next generation sequencing panel of 46/50 genes to identify potential therapeutic targets. Forty-four tumors were of pure endometrioid histotype, while 7 others had undifferentiated, non-endometrioid, or unclassifiable components. β-catenin (Biosciences) and cyclin D1 (Lab Vision) antibodies were utilized for IHC. For β-catenin IHC, presence /absence of distinct nuclear staining was noted. Cyclin-D1 IHC was categorized as either high or low nuclear expression. A third pathologist (BD), blinded to the sequencing results, also analyzed the β-catenin IHC slides. Results: 21/51 tumors had exon 3 CTNNB1 mutations, including 4 of the tumors that were not purely endometrioid. 2/21 cases with CTNNB1 mutation failed to demonstrate nuclear staining. 1/30 wildtype cases had nuclear β-catenin staining in approximately 40% of the tumor cells. All cases, including those with CTNNB1 mutations, exhibited strong membranous β-catenin staining in at least some foci of the tumor. Nuclear expression of β-catenin tended to be scattered and multi-focal. Based on β-catenin IHC, the third blinded pathologist correctly ascertained CTNNB1 mutation status in 48/51 cases, with the exception of the 3 cases noted above. β-catenin IHC had a sensitivity of 90.5% and a specificity of 96.7% in predicting CTNNB1 mutation status, with a false positive rate of 3.3% and a false negative rate of 9.5%. There was no correlation between cyclin-D1 IHC and CTNNB1 mutational status. Conclusions: β-catenin IHC proved to be a reliable screening tool in identifying endometrial carcinomas with CTNNB1 mutation, with discordance between sequencing and IHC identified in only 6% of cases. However, due to the scattered and multi-focal nuclear β-catenin expression, tissue microarrays and small biopsies would be more likely to exhibit false negative results. Background: Transitional cell metaplasia (TCM) occurs in various sites of female genital organs including the uterine cervix. The pathogenetic mechanism has not been clarified, however, TCM of the uterine cervix occurs predominantly in peri-/ postmenopausal women. Previously, TCMs have been described in patients with adrenogenital syndrome or after androgen treatment, all of whom have increased serum androgen levels, which suggests a possible pathogenetic role of androgenic hormone.
Design: To investigate the pathogenetic role of androgenic hormone in the TCM, we compared the distribution patterns and Histoscores of androgen receptor (AR), GATA-3 (a transcription factor involved in androgen regulation), and AKR1C3 (an enzyme involved in androgen biosynthesis) expressions in normal exocervical mucosa in women before age 40 (n=25), senile atrophy (n=23) and TCM (n=29) in the uterine cervix of postmenopausal women.
Results:
In normal exocervical mucosa of young women, AR and GATA 3 were predominantly confined to the basal and parabasal layers with strong intensity, whereas both expressions were significantly extended up to the intermediate and superficial layers in the TCM (P<0.0001). AKR1C3 expression in normal mucosa was mostly confined to basal and parabasal layers with some extension to the intermediate layer, but in the TCM the expression was diffusely extended through the entire layers with weaker intensity. In the senile atrophy, AR and GATA3 expressions were identified throughout the entire layers, but AKR1C3 expression was nearly absent. TCM showed stronger and extended expressions of AR and GATA 3 up to the intermediate and superficial layer compared to senile atrophy, but AKR1C3 expression was significantly increased in the TCM compared to the senile atrophy. Conclusions: Upward extension of AR and GATA 3 expressions in the TCM compared to normal mucosa and senile atrophy may suggest that androgen pathway might be related to the pathogenetic mechanism of TCM. Considering the conversion capacity of AKR1C3 from androstenedione to testosterone followed by aromatization to synthesize 17β-estradiol in the tissue, thicker epithelial layers of the TCM comapared to the senile atrophy might be due to increased estrogen synthesis by AKR1C3 expression. Results: 343 patients were included in this analysis, 17% of which had tumors with an exon 3 CTNNB1 mutation. Patients with tumors that had CTNNB1 mutations were significantly younger and had a higher body mass index compared to women with CTNNB1 wildtype tumors. CTNNB1 mutated tumors were more frequently endometrioid (EEC) histology, more often grade 1, and less often had lymphovascular space invasion. FIGO stage at time of hysterectomy was not significantly different between the CTNNB1 mutant and wildtype groups. Among low grade (grade 1 or 2) EEC, CTNNB1 mutants had higher rates of recurrence (44 vs 25%, p = 0.017). Within this same low grade EEC group, CTNNB1 mutants had worse RFS than CTNNB1 wild type tumors (median 6.14 vs 11.31 years, p=0.039). There were no differences in rates of adjuvant therapy, advanced stage, or TP53 mutations between the CTNNB1 groups within the low grade EEC group. KRAS mutations were more common among CTNNB1 wildtype tumors. Conclusions: CTNNB1 mutations are more common in younger, obese EC patients, women we tend to think of as having good prognosis, hormone-driven malignancies. However, CTNNB1 mutation is associated with incresed risk of recurrence and with significantly decreased RFS in this patient group. Assessment of these mutations may be useful in the up-front identification of women with low grade EC at risk of recurrence. 
Conclusions:
Although small, our study shows that HG-ESS is a molecularly heterogeneous entity and only a small proportion of tumors show the YWHAE-NUTM2 translocation. We found other interesting somatic mutations and amplifications in these tumors. Further studies are needed to assess the frequency of these abnormalities and to better define the category of HG-ESS. All cases of invasive stratified-mucin producing carcinoma demonstrated stratified, immature nuclei with intracytoplasmic mucin which morphologically varied between cases from "mucin-rich" to "mucin-poor" in a similar manner to SMILE. All cases had mitotic figures, apoptotic debris and an intralesional neutrophilic infiltrate was seen in the majority of cases. In cases of invasive carcinoma, the depth of invasion ranged from less than 1 mm to 19 mm. Follow-up was available in 8 cases and ranged from 1 to 36 months (mean 11). Three cases of invasive stratified-mucin producing carcinoma had biopsy or resection proven metastatic carcinoma on follow-up.
Given that SMILE is well rooted as a distinct intraepithelial lesion, we propose the term invasive stratified mucin-producing carcinoma to describe its corresponding invasive carcinoma to maintain consistency in nomenclature and to create a spectrum of cervical neoplasia. Treatment of invasive stratified mucin-producing should not differ from other forms of invasive cervical carcinoma. However, awareness of this entity and its capacity for invasion and distant metastasis is important to ensure adequate patient management. High concordance was observed between preoperative biopsy grade and FS. Depth of MI was concordant in 129 of 133 cases. In 4 cases, where gross MI differed from FS, final was concordant with gross in 2 and FS in 2. Of 48 cases (TS>2cm) with staging, 3 had + LNs (6%), and of 20 cases (TS<=2cm) with staging, 4 had +LNs (20%). 84 pts met gross criteria for staging; 51 were staged: 5 (9.8%) had + LNs. Of those not meeting criteria, 17 were staged: 2 (11.8%)with + LNs. 23 pts met frozen criteria and were staged; 2 (8.7%) had + LNs. Of 124 pts not meeting criteria; 41 were staged: 4 (9.8%) had+ LNs. Conclusions: Addition of FS analysis to preoperative biopsy and intraoperative gross assessment has little impact on intraoperative decisions, making IOFS redundant. Neither gross nor frozen criteria currently used are accurate in identifying pts with risk of nodal disease. Future efforts should focus on developing tools to improve accuracy and decrease unnecessary morbidity. 
Intraoperative Consultation in Low Grade
Genomewide Copy Number Analysis of Müllerian Adenosarcoma Identified Increased Chromosomal Instability and Chromothripsis-Like Profiles in the Aggressive Subgroup
P16 Expression and Biologic Behavior of Flat Vulvar Low-Grade Squamous Intraepithelial Lesions (LSIL)
Natasha Lewis, Kruti Maniar. Northwestern University-Feinberg School of Medicine, Chicago, IL. Background: Flat vulvar LSIL (VIN 1, "flat condyloma") is uncommon and poorly understood. Current recommendations endorse treating all vulvar LSIL conservatively, with some controversy as to whether VIN 1 represents a true biologic entity. However, a significant proportion of VIN 1 has been shown to harbor high-risk HPV, with an as yet unclear rate of progression to higher grade lesions. We aimed to better characterize the biology of flat vulvar LSIL and assess a potential prognostic role for the biomarker p16 (overexpressed in high-risk HPV-related lesions) for subsequent development of HSIL. Design: All available cases of flat vulvar LSIL from 2003-2010 were reviewed by two pathologists for confirmation of diagnosis, with p16 immunostaining (Biocare, clone G175-405) performed in cases with sufficient material. Clinical data and pathology results were obtained from medical records. The frequency of subsequent development of vulvar HSIL/invasive carcinoma was compared between p16(+) (diffuse block reactivity) and p16(-) (all other expression patterns) cases using the Fisher exact test. Results: 51 cases of flat vulvar LSIL were identified from 50 patients (age range 22-73 years, median 39.5 years). 2 of 51 cases (4%) showed p16 positivity. Follow-up data was available in 34 cases (follow-up range 0.4-132.9 months, mean 58.0 months). 1 of 2 p16(+) cases and 1 of 48 p16(-) cases with follow-up developed subsequent vulvar HSIL (VIN 2-3) (p=0.079). Mean time from biopsy to development of vulvar HSIL was 8.6 months. For the 18 patients with treatment information available, 10 (56%) received treatment after biopsy (CO2 laser vaporization, imiquimod, cryotherapy, trichloroacetic acid or excision). 1 of 2 p16(+) cases (50%) and 11 of 48 p16(-) cases (23%) had highgrade HPV-related lesions in additional lower anogenital tract sites (cervical HSIL, invasive cervical squamous cell carcinoma or adenocarcinoma) (p=0.426). Conclusions: Vulvar LSIL is infrequently p16(+) (4%), suggesting cell cycle disruption by high-risk HPV is uncommon in these lesions. Few patients with vulvar LSIL developed subsequent higher grade vulvar lesions (5.9% of all cases with follow-up), which may be partly due to the frequent use of destructive treatment; however, this rate was higher among p16(+) cases (50%) than p16(-) cases (2.1%). While this difference was not statistically significant, the findings suggest that p16 positivity in vulvar LSIL may help predict subsequent development of HSIL. Further studies are warranted to better define the significance of this marker in flat vulvar LSIL. Conclusions: Our findings demonstrate the utility of next generation sequencing-based fusion assay in the diagnosis of ESS.
The Utility of Next Generation Sequencing-Based Gene Fusion Detection Assay in the Diagnosis of Endometrial Stromal Sarcoma
B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Tissue Samples
Li Liang, Yi Jiang, Jun-song Chen, Na Niu, Jinsong Liu. The University of Texas MD Anderson Cancer Center, Houston, TX; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Background: Immune therapy against certain immune checkpoint inhibitors, such as PD-L1, a member of the B7 family, has been quite effective in suppressing the growth of a subset of incurable cancers. However, it is unclear why anti-PD-L1 therapy only works in a subset of cancers, and it is possible that other members of the B7 family may be involved in suppressing the immune response. B7-H4, a novel member of the B7 family, has been demonstrated to inhibit T-cell responses by inhibiting T-cell proliferation and cytokine production. We therefore examined B7-H4 expression patterns in ovarian cancer. Design: We investigated B7-H4 expression patterns in 306 tissue samples of ovarian serous carcinoma using tissue microarrays and anti-B7-H4 antibody (D1M8I, 1:200; Cell Signaling Technology). The immunohistochemistry results were scored as follows: 0, no staining; 1, apical membranous and cytoplasmic staining; 2, mixed pattern with circumferential membranous staining in less than 10% of tumor cells; 3, circumferential membranous staining in at least 10% of tumor cells. Results: B7-H4 protein was expressed in 267 (91%) of 293 high-grade serous carcinomas, of which 63 samples were scored as 1, 70 samples were scored as 2, and 134 samples were scored as 3. B7-H4 protein was expressed in 9 (69%) of 13 lowgrade serous carcinomas, of which 6 samples were scored as 1, 2 samples were scored as 2, and 1 sample was scored as 3. B7-H4 protein expression was not associated with disease stages. However, there was significant difference in B7-H4 protein expression between high-grade and low-grade serous carcinoma (Fisher's exact test, P<0.05). Conclusions: Primary glial and neuronal tumors of the ovary can arise independently or in association with other ovarian germ cell tumor components. Pathologists should be aware of these probably underdiagnosed tumors. Background: Ovarian small cell carcinoma, hypercalcemic-type (OSCCHT) is an extremely aggressive neoplasm that usually occurs in young women and is associated with hypercalcemia and poor prognosis. Although the classic tumor morphology is composed diffuse sheets of small cells with scant cytoplasm and follicle-like spaces, a large cell variant with eosinophilic cytoplasm has been described. We performed comprehensive genomic profiling to uncover clinically and pathophysiologically relevant genomic alterations in OSCCHT. Design: DNA was extracted from formalin-fixed, paraffin-embedded tissue from 12 cases of OSCCHT (including 10 cases of classic morphology and 2 cases exhibiting a large cell variant morphology). Comprehensive genomic profiling (CGP) based on targeted next generation sequencing (NGS) was performed on hybridization-captured, adaptor ligation-based libraries in a CLIA-certified lab, by surveying 315 genes for all classes of genomic alterations (base substitutions, insertions/deletions, copy number alterations, and rearrangements). Results: CGP revealed inactivating SMARCA4 alterations and a low mutation rate profile (average 3.9 genomic alterations per case) in 100% (10 of 10) OSCCHT with classic morphology. In contrast, 2 of 2 cases of OSCCHT with large cell variant morphology exhibited a high mutation rate (hypermutated) profile (average 69.5 genomic events per case) with alterations in ARID1A, which co-exists and forms part of the same SWI/SNF chromatin remodeling complex as SMARCA4. Conclusions: Our results support a role for alterations of the SMARCA4/ARID1A SWI/SNF chromatin remodeling complex in the pathogenesis of OSCCHT. However, different mutation rate and genomic profiles seen in classic versus the large cell variant of such strongly suggest that they may be biologically distinct entities. Our results also support the notion that targeted therapies against SMARCA2 ATPase or EZH2 inhibitors, which may be effective in SMARCA4-deficient tumors, should be considered in OSCCHT and that immunotherapies may be considered in the large cell variant.
High NRF2 with p62 Co-Expression in PTEN Null Endometrial Endometrioid Carcinomas Is Associated with Different Survival Impact in Early vs Late Stage Disease
Genomic Analysis of Ovarian PNETs by Next Generation Sequencing Reveals Recurrent Copy Number and TP53 Alterations
Christopher Liverman, Nancy M Joseph, Charles Zaloudek. University of California San Francisco, San Francisco, CA. Background: Primitive neuroectodermal tumors (PNETs) of the ovary are rare germ cell tumors thought to arise from the immature neuroepithelium of teratomas. Due to their rarity, the molecular underpinnings of ovarian PNETs are largely unknown. Peripheral PNET/Ewing Sarcoma shows translocation of the EWSR1 gene. A subset of central nervous system PNETs show MYCN or MYC amplification. The molecular drivers of ovarian PNET remain unknown. The purpose of this study was to determine the genomic alterations in ovarian PNETs using FISH analysis and next generation sequencing.
Design:
We identified six cases of previously well-characterized ovarian PNET from our consult files. DNA was extracted from formalin-fixed paraffin embedded tissue. Capture-based next generation sequencing was performed using an assay that targets the coding regions of over 500 cancer genes as well as select introns, covering a total of 2. 
Expression of Claudin-18, a Novel Gastric Marker, Is Associated with Poor Prognosis in Cervical Adenocarcinoma
Daichi Maeda. Akita University, Graduate School of Medicine, Akita, Japan. Background: Gastric-type mucinous adenocarcinoma (GA) is now recognized as a distinct subtype of uterine cervical adenocarcinoma, and its prognosis has been reported to be poor. However, morphological distinction between GAs and non-GAs are often difficult. We have previously shown that a novel gastric marker claudin-18 (CLDN18) is almost specifically expressed in GAs. We believe that positivity for CLDN18 along with non-diffuse pattern of p16 staining are hallmark immunohistochemical features of GAs. In this study, we investigated clinical significance of these immunohistochemical markers along with a conventional gastric marker, HIK1083, in cervical adenocarcinomas. Design: This retrospective study was based on 65 cases of cervical adenocarcinoma. Morphologically, 9 cases revealed typical GA features. In 4 cases, the possibility of GA was raised. Most other cases were classified as usual-type adenocarcioma. Immunohistochemistry for CLDN18, HIK1083 and p16 was performed. The association between expression of these markers and clinicopathological factors including parametrial invasion, vaginal invasion, lymph node metastasis, T-stage and overall survival was then evaluated. Results: CLDN18-positivity (≥10%) and HIK1083-positivity (≥10%) was observed in 14 cases (21.5%) and 7 cases (10.7%), respectively. Vaginal invasion was more frequent in CLDN18-positive cases. (p=0.004) Further, CLDN18 expression was associated with poor overall survival. (p=0.0172) On the other hand, HIK1083 expression did not correlate with any of the clinicopathological factors assessed. Non-diffuse pattern of p16 staining (<80%) was observed in 17 cases (26.2%), and it was associated with lymph node metastasis (p=0.0352) and poor overall survival (p=0.0437).
Conclusions:
Expression of CLDN18, a novel gastric marker, is a poor prognostic indicator in uterine cervical adenocarcinoma. Immunohistochemistry for CLDN18 and p16 is usuful not only for the diagnosis of GAs, but also for the prediction of patient outcome in cervical adenocarcinoma in general. 
VaM tends to be a disease of elderly women with genetic alterations detected in only a quarter of cases with cKIT mutations most frequently detected. In this series, most tumors had an epicenter in the distal vagina. NRAS and cKIT mutations were geographically restricted. Cases with cKIT mutation were restricted to the distal vagina suggesting that distal VaM may be more similar to vulvar melanoma. Tumor location within the vagina may predict the likelihood of a specific molecular alteration. atypia, cellularity, mitotic index, type of necrosis (coagulative, hyalinizing/ischemic, or uncertain), cell morphology (epithelioid vs. spindled vs. myxoid) and status of tumor margins or adhesion to adjacent organs were recorded. Medical records were reviewed for age, hormone use, tumor size, number and location, surgical procedure, therapy, and follow-up. Results: 24 patients with extrauterine smooth muscle tumors were identified. Patient age ranged from 31 to 77 years (mean 51). Extrauterine sites of involvement included pelvic peritoneum (n=19), pelvic lymph node (n=1) and lung (n=2), Two had widespread pelvic and abdominal involvement (disseminated peritoneal leiomyomatosis). Ten were isolated tumor masses. All but 4 were associated with synchronous or metachronous (n=9) uterine leiomyomas. Of the 24 extrauterine smooth muscle tumors, 3 were epithelioid, 2 were atypical with bizarre nuclei, and 2 were diagnosed as smooth muscle tumors of uncertain malignant potential (STUMP) on the basis of epithelioid histology and increased mitotic index. Two were lipoleiomyomas and the remainder had leiomyoma histology. Two patients (8%) developed recurrent pelvic disease at 2 and 11 years, respectively. One of the recurrences was usual leiomyoma while the other was a STUMP based on increased mitotic index and increased cellularity. No patient succumbed to disease in the follow up period. Conclusions: Female genital tract smooth muscle tumors that present in unusual sites are problematic with respect to diagnosis and clinical management. Our data suggest that while most of these tumors are associated with banal (leiomyoma) histology and a benign clinical course, a subset may exhibit atypical histology. In addition, the concept of benign metastasizing leiomyoma should not be limited to those cases with pulmonary involvement as 7 cases in this series developed pelvic and/or lymph node recurrences in absence of pulmonary disease. Background: Gastric-type cervical adenocarcinomas (GCAs) are under-recognized, aggressive, chemorefractory neoplasms that are not associated with HPV. The pathogenesis of GCA is poorly understood, due to their rarity. We sought to characterize the mutational landscape of GCAs using a targeted capture next-generation sequencing assay. Design: DNA extracted from tumor and matched normal formalin-fixed paraffinembedded tissue from 10 GCAs was subjected to next-generation sequencing targeting all exons and selected introns of 341 actionable cancer genes (MSK-IMPACT). Somatic single nucleotide variants (SNVs) were identified using MuTect, and small insertions and deletions (indels) were detected using Strelka and VarScan 2. Copy number alterations (CNAs) were identified using VarScan 2. The repertoire of mutations and gene copy number alterations of GCAs was compared to that of common-type HPV-associated cervical carcinomas as reported by Ojesina et al (Nature 2014; 506:371-5) .
Evaluating Mixed Endometrial Carcinomas with a Panel of Immunohistochemical Markers
Results: We obtained high-quality sequencing data for 6 matched tumor-normal GCA pairs, and for 2 tumors without matched normal tissues. The targeted sequencing analysis yielded a median depth of coverage of 347x (range 57-741x).
We identified a median of 1.5 somatic mutations (range 0-9) in the 6 cases where matched normal tissue was available. Three genes were recurrently targeted by mutations in these 6 GCAs, namely TP53 (hotspot R282W, Q192*), GNAS (two R201H hotspot mutations) encoding a G protein frequently found to be somatically mutated in tumors of the biliary tract, pancreas, small intestine and pituitary, and in SMAD4 (Q534*, R361S), a tumor suppressor gene frequently mutated in gastrointestinal cancers and a mediator of the TGF-beta signaling pathway. Mutation analysis of the two GCAs without matched normal tissue revealed the presence of mutations in TP53, but also DNA repair-related genes, as well as a CDKN2A frameshift mutation.
In comparison with HPV-associated cervical carcinomas, we found GCAs to more frequently harbor GNAS and SMAD4 mutations and CDKN1B (12p13.1) amplifications.
Conclusions:
The results of our exploratory pilot study provide evidence to suggest that the repertoire of somatic mutations and gene copy number alterations in GCAs is distinct from that of HPV-associated cervical carcinomas, and identifies novel pathogenetic bases for this rare, aggressive disease. The figure shows increasing loss-of-heterozygosity with progression from SBT to LGSC to UC in one patient.
The results show genotypic alterations underlying tumor progression. RAS mutations predominate in low-grade tumors, with emergence of P53 (and other) mutations and increasing LOH as the tumors progress. Background: Adult granulosa cell tumor (AGCT) of the ovary is considered a tumor of low malignant potential capable of recurrence and metastasis while fibroma is benign; therefore distinction between the two entities is clinically important. Some fibromas can have minor sex cord elements (SCE), arbitrarily defined as less than 10% of tumor volume. Fibromas with SCE >10% are considered "granulosa cell tumors in a prominent fibrothecomatous background", also referred to as "granulosa-theca cell tumor" (GTCT).
GTCT is a poorly defined entity that can be challenging to distinguish both from spindled AGCT and cellular fibroma. In limited studies, these tumors appear to have excellent prognosis. AGCTs are known to almost universally harbor a FOXL2 mutation, while fibromas do not. The FOXL2 mutation status has not been evaluated in GTCT. Design: Twelve granulosa theca cell tumors were identified. DNA was extracted and the 5' portion of exon 1 of the FOXL2 gene was amplified using specific PCR primers. 
In our study, half of the GTCTs demonstrated FOXL2 mutations, while the other half were wild-type. None of the tumors with low volume of granulosa cells (≤20%) showed FOXL2 mutations. Future studies of larger size and longer follow up should test whether the 10% cutoff for SCE in fibrothecoma should be moved to <30%. Cases with 40% or more SCE are most likely to harbor FOXL2 mutations, raising the question of whether these are more appropriately classified and treated as AGCT. From a practical standpoint, these results raise the question as whether all morphologic diagnoses of granulosa theca cell tumor should be evaluated by FOLX2 mutation testing since a positive finding may result in a more definitive classification as AGCT. Background: Due to a lack of specific disease symptoms, only 20% of patients with ovarian cancer (OC) are diagnosed at Stage 1, when therapeutic intervention would be most effective. This highlights the need to identify biomarkers for the diagnosis of early stage OC. Autoantibodies to cancer antigenscan be detected up to 5 years before a tumour can be identified by other means and are therefore extremely attractive analytes for inclusion as an early stage OC test. However, selection of autoantibodies to include as disease specific markers is hindered by inadequate understanding of the natural autoantibody (NAA) repertoire of healthy individuals and inappropriate choice of control cohorts in autoantibody biomarker discovery studies. Profiling the NAA repertoire of healthy people will identify antigens that can be "subtracted" from a biomarker panel for detection of early OC. Design: Study approval was obtained from SJH/AMNCH research ethics committee. Using protein arrays from the Human Expression Library (hEx1) brain library (ImaGenes, Germany), 22 early and 20 late OC serum samples, and 15 benign ovarian disease samples were profiled. These profiles were compared to 436 other samples (132 healthy, 95 cancer, 69 autoimmune, 140 other disease).
Biomarker Selection in Early Ovarian
Results: Autoantibodies detected in ≥ 30% of cohort samples were considered to be part of the autoantibody repertoire. Approximately 250 proteins have been identified as being associated with initiating an autoantibody response in early OC (detected in early OC samples and not associated with late OC samples, healthy/control samples or with benign ovarian disease). The frequency of autoantibodies to these proteins have been compared with all samples screened to enable identify antigens that can be "subtracted" from a biomarker panel for detection of early OC. Conclusions: Autoantibody profiling of serum samples from OC patients and controls has supported the identification of a large number of autoantibodies which may be involved in disease formation and/or progression. The selection of autoantibodies for further biomarker validation has been supported by identification of the NAA profile and ensuring the NAA proteins are subtracted from any disease associated biomarker panel.
HE4 Has a Role in Treatment Planning in Endometrial Cancer
Sharon O'Toole, Rizmee Shireen, Seamus McDonald, Lucy Norris, Anthony Cooney, Feras AbuSaadeh, Waseem Kamran, Cliona Murphy, Nadine Farah, Tom D'Arcy, Noreen Gleeson, John J O'Leary. Trinity College Dublin, Dublin, Ireland; St. James's Hospital, Dublin, Ireland; Coombe Women's and Infants University Hospital, Dublin, Ireland. Background: Human epididymis protein 4 (HE4) is a secreted protein that is overexpressed in some cancers. HE4 is emerging as a useful biomarker in diagnosis and management of endometrial cancers. The aim of this study was to evaluate the role of serum HE4 in the treatment planning for women diagnosed with endometrial cancer. Design: Patients undergoing surgery for endometrial disease were recruited into this study and had pre-operative serum samples taken, n=210. Demographic, clinical, radiological and laboratory data were reviewed. HE4 and CA125 serum levels were analysed using the Fujirebio Diagnostic ELISA Kits and results correlated with clinicopathological details. Standard cut-off points of 70 pmol/L for HE4 and 35 U/ ml for CA125 were used. Results: HE4 showed a sensitivity of 62% and specificity of 98% for detection of endometrial cancer. CA125 had a very low sensitivity of 15% for endometrial cancer diagnosis. HE4 was significantly higher in more advanced poorly differentiated disease. HE4 displayed a sensitivity of 76% and 78%, respectively for predicting outer half myometrial invasion and lymphovascular space invasion.
Conclusions: HE4 has a role in endometrial cancer diagnosis and prognosis and may have a role in determining patients that require lymphadenectomy. For women diagnosed with endometrial cancer, HE4 has the potential to stratify them into treatment regimens where the most appropriate treatment can be delivered resulting in improved quality of life and outcome for endometrial cancer patients. Results: A total of 1,893 women with CIN2+ were identified, of whom 1403 (74%) were HPV vaccine eligible. A total of 253/1403 (18%) received at least one dose of an HPV vaccine and 150/1893 (7.9%) received at least one dose prior to their CIN2+ diagnosis. The overall CIN2+ rate decreased from 1062 to 854 per 100,000 women annually between 2008 and 2013. For women aged 25-29 and 30-39, there were no clear trends in the rate of CIN2+ lesions and averaged 230 and 378 per 100,000, respectively. In women aged 18-20 and 21-24 years, the incidence of CIN2+ lesions trended downward from 153 to 51 and from 336 to 188 per 100,000 women, respectively. In all age groups, the rates of CIN2 were higher than CIN3. AIS was identified in 2 patients age <25 years (0.63/100,000) and 26 patients >25 years (5.37/100,000). Vaccine types were Gardasil (230) Cervarix (2), and unknown type (27). Three, two, and one vaccine doses were documented in 63.8%, 19.7%, and 16.6%, respectively. First vaccination was at age 16-20 years in 45 (20.5%), 21-24 years in 114 (21%), and 25-29 years in 58 (15.2%). Vaccination rates in Whites, African American and Hispanic population were 20.2%, 19.3% and 9.5% for those who were vaccine eligible, respectively.
HPV Vaccination Status in Patients with High Grade Cervical Precancerous Lesions
Conclusions:
The frequency of CIN2+ in Davidson County among women 18-39 years is approximately 1 per 1000 per year and AIS lesions are uncommon. The frequency of CIN2+ is trending down in woman 18-24 years, likely related to changes in screening. Gardasil was almost exclusively used, but vaccination rates are low, and provided too late for some women. Vaccination rates were lower in Hispanics than in White and African American populations. Design: Cross-sectional descriptive study was carried out (December 2011 to March 2014) using liquid based (Turbitec Ⓡ ) cytology. The cytological findings were classified according to the 2001 Bethesda System. Colposcopy with or without biopsy was performed whenever atypical cells (ASC-US or ASC-H) or a lesion were identified. Genotyping of the HPV profile was performed. Results: The cytological survey included 5038 women (25-54 years old), which represents 17,53% of the target population (5038/28651) according the Census 2012. The results of the cervical cytology were: NILM (4469; 89%) and SIL/carcinoma (569; 11%) -LSIL (194; 34,1%), ASC-H (39; 6,8%), HSIL (83; 14,6%), AGC (4; 0,7%) and carcinoma (1; 0,2%). From the 124 cervical biopsies performed, the results were correlated as follow:
10% of the collected samples were sequenced for HPV DNA, revealing 34 distinct types of HPV with 12 HPV-HR (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) . Conclusions: This is the first attempt to document the epidemiological profile of cervical lesions in São Tomé and Príncipe. Our results confirms a public health problem that need further investigation, particularly regarding HPV genotyping profile, in order to define future actions. Background: There is clear evidence indicating that there are two different etiopathogenic pathways for the development of vulvar squamous cell carcinomas (VSCC): one associated with infection by human papillomavirus (HPV), and another independent of HPV. We aimed to determine whether there are any differential characteristics between the two types of VSCCs in a large series of tumors. Design: We included 791 VSCCs from 39 countries during the period 1980-2011. A single paraffin block was available for review of each case. The analysis in all the tumors included histological review, HPV analysis HPV/DNA detection using SPF10PCR/ DEIA/LiPA25 system and p16 immunohistochemistry. The histological evaluation was done blindly to the HPV results and included characteristics of the tumor as well as changes in the adjacent skin. Results: 184 tumors (23.3%) were positive for HPV. There was a strong association between histological type and the presence of HPV (p<0.001). HPV-positive tumors were more frequently basaloid (33.2%), warty (9.2%) or non-keratinizing (19.0%). However, 38.0 were of the keratinizing type. HPV-negative tumors were more frequently keratinizing (78.1%), but were occasionally basaloid, warty or non-keratinizing (6.1, 2.8 and 10.7%, respectively). HPV positive VIN (vulvar intraepithelial neoplasia) were frequently of basaloid/warty type (88.0%). However, 12.0 of them showed differentiated features. Contrarily, VIN lesions in HPV-negative tumors were frequently of the differentiated type (78.9%), but 21.1 of the VIN lesions showed basaloid/warty features. Although several histological characteristics were more frequently associated with HPV-negative VSCC (individual keratinization, highly differentiated cells, invasive front with small nests, presence of lichen sclerosus or lichen simple chronicus in the adjacent skin; p<0.001), all of them were also present in a number of HPV-positive tumors and none of them allowed differentiation between HPV-positive and -negative VSCC. p16 was positive in 85.9% of the HPV-positive and in 4.3% of the HPV-negative tumors (p<0.0001). Conclusions: Histological criteria do not allow differentiation between HPV-positive and -negative VSCC. p16 is a good surrogate marker of HPV etiology in the absence of HPV DNA detection. Background: IVL is a benign smooth muscle proliferation characterized by intravascular growth. Despite the well delineated molecular genetic alterations of uterine leiomyomas and leiomyosarcomas, there is only a single comprehensive molecular genetic study of IVL showing several recurrent copy number aberrations including 22q12-q13 (66%) and 10q22 (33%) alterations (%11 with both abnormalities). Studying IVL expression patterns in correlation with their genetic background may potentially provide insight into their biology. Design: 26 IVL were evaluated for 5 immunohistochemical markers: p16, Carbonic Anhydrase IX, and INI1 for the "potential" 22q deletion group and CyclinD1 (due to close proximity to FAM22A locus also altered in endometrial stromal sarcoma which correlates with CyclinD1 expression) for the "potential" 10q22 duplication group. In addition, FH was also analyzed as one of the reported cases had a 1q42-q44 deletion. Staining was evaluated in tumor and myometrium with a semiquantitave method: 0 (no staining), 1 (minimal, <5%), 2 (focal, 5-24%), 3 (multifocal, 25-50%) and 4 (diffuse, >50%). Data was analyzed by student t-Test. (p<0,001) . Multifocal/diffuse p16 and CyclinD1 positivity was detected in 16 (61%) and 6 (23%) IVL, 5 (19%) coexpressed both. Overall, 13 out of 15 usual, 4 with hydropic change, 3 out of 4 cellular, and 1 with fat IVLs had more extensive p16 than CyclinD1 positivity. Two epithelioid IVL had multifocal/diffuse CyclinD1 positivity but only absent/focal p16 positivity. INI1 showed nuclear staining in all IVL and nuclear and cytoplasmic staining in myometrium. FH was retained and Carbonic Anhydrase IX was negative in all cases. Conclusions: Our immunohistochemical findings are in parallel to previously reported molecular profile of IVL suggesting pathways that may be relevant to 22q deletion and 10q duplication with p16 and Cyclin D1 as their respective biomarkers. Of interest, IVL with epithelioid morphology appears to show a phenotype vastly driven by cyclinD1 expression with potential biological implications. Background: Uterine tumors resembling ovarian sex cord tumors (UTROSCT) are rare uterine mesenchymal neoplasms characterized by a predominance of sex cord-like elements. In addition to diverse architectural patterns, UTROSCT can also variably express epithelial, smooth muscle, and sex cord markers. To date, these tumors lack the t(7;17) translocation seen in several types of endometrial stromal tumors (EST). The molecular cytogenetics of this polyphenotypic entity have not been well-characterized. In this study, we utilized a molecular inversion probe (MIP) array to examine genomewide copy number changes in a series of UTROSCT. Design: Five cases of UTROSCT were identified from hospital archives. Genomic DNA was extracted from formalin-fixed, paraffin-embedded sections. OncoScan FFPE Assay (Affymetrix) was used to assess genome-wide copy number variations (CNVs) and 74 actionable mutations in 9 genes. Data analysis and visualization was performed in Nexus Express for OncoScan (BioDiscovery) and Chromosome Analysis Suite (ChAS; Affymetrix).
Intravenous Leiomyomatosis (IVL), from Molecular Genetics to
Results:
All 26 IVL showed differential expression of either CyclinD1 or p16 (mean scores 1.46 and 2.73) in comparison to myometrium (mean scores 0.08 and 0.15)
The most prominent CNV in UTROSCT was a recurrent gain of chromosome 1q, seen in 3 of 5 cases. In all three cases, the gain (~104 Mb) involved most of the q arm extending from q21.1-q44. In one case, the duplication resulted in 4 copies of the q arm. The clinicopathologic features of these three cases included age range from 55 to 68 years, tumor size from 6 to 17 cm, and disease-free interval from 2 months to 4 years. Morphologically, these three tumors exhibited focally increased mitotic activity and cytologic atypia compared to the other two cases without 1q gains. The second most frequent CNV involved chromosome 11q. Two of the three cases with 1q gains also showed a 35 Mb homozygous deletion in 11q and an 83.7 Mb heterozygous deletion in 11q, respectively. Additional CNVs found in UTROSCT included gains in 7q and 8q and losses in 6q and 17p. Somatic mutation analysis was negative in all cases. Conclusions: CNVs have been identified in a series of UTROSCT, a rare uterine neoplasm that is considered distinct from other endometrial stromal tumors. The majority of UTROSCT cases displayed a recurrent gain in chromosome 1q, with no cases exhibiting the EST-associated t(7;17). This study demonstrates the feasibility of genomic profiling of rare archived mesenchymal uterine lesions by MIP array.
Mismatch Repair (MMR) Protein Deficiency in Early Stage Ovarian Carcinomas. A Study by Spanish Ovarian Cancer Research Group (GEICO)
Jose Palacios, Ana Gutierrez-Pecharroman, Eva Cristobal, Jose Antonio LopezGuerrero, Ignacio Romero, David Hardisson, Francisco Vera, Begona Vieites, Angel Garcia, Javier Ibarra, Sofia Hakin, Rosa Guarch, Encarna Andrada, Santiago Montes, Francisco Pastor, Maria C Gomez, Maria C Gomez, Andres Poveda. Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; Spanish Ovarian Cancer Research Group, Barcelona, Spain. Background: While there has been extensive investigation of MMR deficiency in colorectal and endometrial cancer, MMR deficiency in ovarian cancer is relatively underinvestigated. In this study, we analyse the frequency of MMR protein deficiency in early stage ovarian cancer and its relationship with morphological and immunohistochemical features. Design: A total of 287 stage I and II of ovarian carcinomas were collected retrospectively by the Spanish Group for Ovarian Cancer Research (GEICO) from the archives of 24 Spanish hospitals. Tumours were classified into 6 different histological types according to morphological and immunohistochemical features (WT1, p53, p16, oestrogen receptor, progesterone receptor, ARID1A, Napsine-A and HINF1B). In addition, the expression of MLH-1, PMS-2, MSH-2, MSH-6, β-catenin and HER2 protein were analysed on tissue microarrays for all the samples. Results: After centralized histological and immunohistochemical evaluation, the tumours were classified as high grade serous carcinoma (98 cases), low grade serous carcinoma (23 cases), high grade endometrial carcinoma (25 cases), low-intermediate grade endometrial carcinoma (66 cases), mucinous carcinoma (26 cases) and clear cell carcinoma (49 cases). MMR protein deficiency (MMR-pd) was detected in a total of 17 cases (6%), MLH1/ PMS2 loss was observed in 7 cases (2.4%), MSH2/MSH6 loss in 7 cases (2.4%), PMS2 loss in 7 cases (2.4%) and MSH6 loss in 10 cases (3.5%). MMR-pd was statistically associated with the histological type, since it was detected in 15.2 %, 12%, 4.1%, 3.8%, 1% and 0% of low/intermediate grade endometrial carcinoma, high grade endometrial carcinoma, clear cell carcinoma, mucinous carcinoma, high grade serous carcinoma and low grade serous carcinoma respectively (P=0.003). MMR-pd was also more frequently observed in tumours with a "wild type" p53 expression pattern (p=0.012) and reduced or absent ARID1A expression (P<0,001). Conclusions: MMR deficiency is infrequent among early stage ovarian carcinomas. Most MMR deficient tumours are endometrioid carcinomas and the pattern of MMR protein loss suggests a higher frequency of hereditary (associated to Lynch syndrome) than sporadic cases.
Investigation of Napsin-A in Atypical Versus Usual Endometriosis
Cherie Paquette, M Ruhul Quddus, C James Sung, Joyce J Ou, W Dwayne Lawrence. Women and Infants Hospital, Providence, RI; Brown University School of Medicine, Providence, RI. Background: Atypical endometriosis (with cytologic atypia including crowding, hyperchromasia, and nuclear enlargement) is associated with risk of clear cell (CCC) or endometrioid carcinoma. Studies have demonstrated ARID1A and PIK3CA mutations, loss of heterozygosity, and other molecular alterations in endometriosis supporting a pre-neoplastic categorization, with few studies focusing on atypical endometriosis. With the recent demonstration of Napsin-A immunohistochemical (IHC) stain positivity in the majority of CCC, this raises the question of whether atypical or usual endometriosis may also be positive for Napsin-A. Endometriosis, to our knowledge, has so far not yet been studied using Napsin-A. Napsin-A positivity in usual or atypical endometriosis would strengthen the etiologic link with CCC. Design: The records of one institution were searched from 2007-2015 for all atypical endometriosis and cases of endometriosis adjacent to CCC. Additionally, 10 cases of usual endometriosis were selected. Napsin-A IHC was performed on a representative slide from each case and scored positive if the endometriotic glands had cytoplasmic stain of at least moderate intensity. Results: 21 cases of atypical endometriosis (range 25-61, mean 41.3 years), 8 of endometriosis adjacent to CCC (range 52-78, mean 62.3 years), and 10 of usual endometriosis (range 24-62, mean 41.2 years) were included. The majority (87.5%) of CCC were positive for Napsin-A. The positivity for Napsin-A in endometriosis is as follows: 52.3% for atypical endometriosis, 37.5% for endometriosis adjacent to CCC, and 10% for usual endometriosis. Figure 1 below shows atypical endometriosis on H&E and Napsin-A stain.
Conclusions: Here we demonstrate that Napsin-A is positive in 52.3% of atypical endometriosis cases, while usual endometriosis is rarely Napsin-A positive. This supports the hypothesis that atypical endometriosis is a precursor lesion of CCC. Further, these results suggest caution in using Napsin-A to confirm a diagnosis of CCC in small biopsies without overt evidence of invasion: a focus of atypical endometriosis may have cytologic atypia and Napsin-A positivity. Further studies are needed to elucidate molecular changes leading to Napsin-A expression in atypical endometriosis. Background: This survey based study was undertaken to inform on variability in processing, diagnosis and reporting of endometrial carcinoma among the membership of the ISGyP. Design: A 112 question survey was circulated among the membership of the ISGyP using a web-based online tool (www.surveymonkey.com) during July 2015, with three reminders sent. Results: 47% (242/514) of members responded to the survey. 87% were from North America, Europe, or Australia. Depth of myoinvasion (93%), assessment of tumor type (88%), and tumor grading (75%) were consistently evaluated at frozen section; other parameters were not (cervical, adnexal and vascular invasion). At grossing, tumor size and site were recorded consistently;sectioning protocols were variable with respect to sectioning of tumor, normal endometrium, uninvolved adnexa and omentum. Lymph nodes were entirely submitted by 93%. Immunohistochemistry use was inconsistent for tumor subtyping (22-45% depending on subtype). FIGO was the most commonly used grading system (97%);17% indicated reporting a mixture of grades for mixed patterns. 86% reported recording inner/outer half myoinvasion but percentage myoinvasion was reported by 52% and distance to serosa by 59%. Patterns of myoinvasion (51%) and depth of cervical tumor invasion (60%) were variably reported. Tumor involvement of deep adenomyosis (10%), isolated tumor cells in lymph nodes (65%), tumor cells in tubal lumen (5%) and keratin granulomas (2%) were sometimes used to upstage tumors. Use of hormone receptor staining, mismatch repair protein analysis, ploidy and molecular studies were extremely variable. 9% of respondents did not report stage on the pathology report; the remainder used FIGO and/or AJCC or UICC staging systems. WHO 2003 (16%,) , WHO 2014 (71%) and EIN (13%) were used for reporting precursor lesions of endometrioid adenocarcinoma. Conclusions: This survey demonstrates areas of significant variability in the processing, diagnosis and reporting of endometrial carcinoma. A consensus conference is planned to attempt to standardize these parameters. adenosquamous type). Of 49/52 patients with follow-up (6, range 1-15 yrs), 4 died of disease (1, 3, and 11 yrs)(1 usual, 3 gastric), 2 were alive with disease (usual)(3 and 4 yrs)and 1 died of unrelated causes at 9 yrs.5/9 patients with gastric EEC were AW (1, 6 and 7 yrs, 3 stage I, 1 stage II and 1 stage III). Conclusions: EEC with pattern A/B of invasion are usual type, stage I and have good prognosis. Gastric ECC is not an infrequent histotype as much as we are able to recognize its morphological characteristics. It presents in older women compared with usual type, that have higher stage tumors. Endometrioid ECC is also seen at older age and has a pattern C of invasion but does not affect prognosis.
PD-L1 Expression in Malignant Mixed Mullerian Tumors: A Potentially Actionable Biomarker
Andre Pinto, Nicholas Mackrides, Mehrdad Nadji. University of Miami / Jackson Memorial Hospital, Miami, FL. Background: Malignant Mixed Mullerian Tumors (MMMT), also known as carcinosarcomas, are aggressive malignant neoplasms with a high recurrence rate and poor prognosis. Despite advances in adjuvant therapies in recent years, the prognosis of these tumors has not improved. In fact, there are currently no consensus guidelines for the treatment of these neoplasms, and the search for targetable biomarkers has not been successful so far. Programmed death-ligand 1 (PD-L1) has emerged as a potential target for therapeutics in a number of malignant tumors, including melanoma, lung and colorectal cancer. In normal conditions, PDL-1 is thought to promote immune homeostasis via a number of pathways, but mainly through downregulation of cytotoxic T-cells. In some human neoplasms, however, overexpression of PDL-1 has been observed, and this phenomenon can modulate the immune system to allow cancer cells to evade host response. In this study we evaluated the expression PD-L1 in a group of MMMTs using immunohistochemistry. Design: A total of twenty nine (29) cases of MMMTs were analyzed, corresponding to tumors originating from uterus (25), ovary (2), fallopian tube (1), and pelvic epithelium (1). The material was retrieved from the files of the Department of Pathology at the University of Miami, Jackson Memorial Hospital. Immunohistochemistry for PD-L1 was performed on paraffin sections and the staining results were assessed semi quantitatively in both epithelial and mesenchymal components of each tumor. Results: Positive reactions (any membranous staining) for PD-L1 were detected in a total of 25/29 tumors (86%). The epithelial components were strongly positive in 19/29 (65%) and weakly positive in 6/29 tumors (21%). The sarcomatous elements were strongly positive in 8/29 (27%) and weakly positive in 3/29 tumors (10%). All tumors with positive sarcomatous components also had staining of the carcinomatous element. Four (4) tumors were negative for PD-L1 in both components. Conclusions: This study shows that PD-L1 is expressed by the majority of MMMTs, predominantly in the epithelial components. This is particularly important since most locoregional recurrences and distant metastases of MMMTs are of epithelial origin. Although clinical studies are needed to demonstrate the efficacy of PD-L1 inhibitors in this particular neoplasm, this finding may serve as a basis for therapeutic approaches using antibodies that have already shown significant value in a number of other malignant tumors. Ana S Pires-Luis, Carla Bartosch, Catarina Meireles, Carla Pinto, Jose M Lopes, Kristen M Shannon, Manuel R Teixeira, Esther Oliva. IPO-Porto, Porto, Portugal; CHSJ, Porto, Portugal; Massachusetts General Hospital, Boston, MA. Background: Women with Lynch syndrome (LS) have a high risk of developing gynecological tumors. Since endometrial carcinoma not uncommonly is the first malignancy, prophylactic hysterectomy has been increasingly implemented. Design: We reviewed the clinicopathologic features of 70 LS patients diagnosed at 3 tertiary referral centers that underwent prophylactic (PH)(n=39) or nonprophylactic (NPH)(n=31) hysterectomy, and evaluated the gross methodology used as well as any differences. Results: Among PH, only 2 out of 39 had an endometrial tumor seen grossly. Total inclusion of the endometrium was performed in 24 (61.5%). Abnormal histological findings were identified in 9 (23.1%): including 3 endometrial endometrioid carcinomas (EECs), 2 macroscopic (1.3 and 4.5cm) and 1 microscopic (0.6cm), and 4 atypical and 6 non-atypical hyperplasias. NPH were performed for endometrial or ovarian cancer treatment. Tumor sampling followed standard protocols. Endometrial carcinomas comprised 26 EEC and 1 clear cell carcinoma (median 3.7cm). Hyperplasia was observed in 10 (33.3%), in 4 showing atypia. Eight (29.6%) tumors were centered in the lower uterine segment. EEC were predominantly well-differentiated (53.8%) and FIGO stage I (77.8%). A papillary architecture was common (51.9%). Most endometrial tumors (81.5%) showed tumor intraepithelial lymphocytes counts ≥42/10HPF and 4 extensive necrosis. Eight patients had ovarian tumors (4 synchronous), including 2 endometrioid carcinomas, 2 clear cell carcinomas, 1 borderline clear cell adenofibroma, 1 Müllerian carcinoma of mixed cell types, 1 PNET and 1 metastatic melanoma. Patients with NPH were older (median age:51 vs. 45 years, p=0.022), had less frequent personal history of other tumors (51.6% vs. 79.5%, p=0.013), lower frequency of MLH1 mutations (12.9% vs. 48.7%, p=0.002) , and higher frequency of MSH6 mutations (29.0% vs. 5.1%, p=0.006) when compared to patients with PH.
Hysterectomy Specimens of Patients with Lynch Syndrome: Clinicopathologic Study of 70 Cases
Conclusions:
The phenotype of LS-associated endometrial and ovarian tumors is variable but frequently includes features not commonly observed in sporadic cancers. Total inclusion of the endometrium should be done in LS patients' uteri without macroscopic lesions as may harbor hyperplasia or early carcinoma. Differences in mutations distribution correlate with the higher risk of endometrial cancer in MSH6 mutation carriers and more frequent history of MLH1 related colo-rectal neoplasms in PH group. (Table 1 ). All cases were re-reviewed to confirm the diagnosis. Immunohistochemistry analysis of S-(2-succino)-cysteine (2SC), a protein modification that accumulates in the presence of increased fumarate concentrations (most likely as a result of FH inactivating mutations) was examined and scored. Immnotains for ER, PR, P16, P53 and Ki-67, and MED12 mutation were included. Histologic analysis of 2SC-positive and -negative tumors were performed. Results: Immunostain for 2SC is specific to USMT and it is either positive or negative. Among 6 different types of USMT, 2SC was positive in order of highest to lowest frequency as: ALM (50%), STUMP (17%), CLM (14%), LMS (3%) and ULM (2%), respectively. When H/E slides were further reviewed, the majority of cases (77%, 27/33) with 2SC positive tumors had FH-associated histologic features. FH-positive tumors also showed different immunoprofile from FH negative tumors. Mutational analysis of FH for 2SC positive tumors is currently ongoing.
Fumarate Hydratase Alterations Detected by S-(2-Succino)-Cysteine Expression in 6 Different Types of Uterine Smooth Muscle Tumors
Conclusions: FH alterations/mutations are very common in ALM, but it can also be seen in other variants of USMT. The findings suggest that histologically-defined tumor types cannot accurately predict FH status. 2SC immunostain can be a useful biomarker for screening for FH-associated USMT and further assist clinical management. Kate Poropatich, Qing Zhang, Julianne Martinez de Ubago, Norma Frizzell, Beihuan Kong, Jian-Jun Wei. Northwestern University, Chicago, IL; Qilu Hospital, Jinan, Shandong, China; University of South Carolina, Columbia, SC. Background: Atypical leiomyoma (ALM) may be divided into two types based on their characteristic nuclear features. The recently described uterine smooth muscle tumors with fumarate hydratase alterations (SMT-FHs) seem to have similar nuclear features as type I ALM. In this study, we want to investigate whether histologicallydefined types I and II ALM can be supported by molecular findings of FH status and other genetic alterations. Design: A total of 53 ALM were selected that met the Stanford criteria and were further divided into type I (n= 30) and II (n= 23) based on nuclear features. Other histologic features were also analyzed, including cellularity, density of atypia, size of nucleoli, perinuclear halo, staghorn vessels and eosinophilic globules. IHC analysis of S-(2-succino)-cysteine (2SC) (most likely as a result of FH inactivating mutations) and mutation analysis of p53, MED12, PTEN and HMGA2 genes were performed. Results: Two histologic types of ALM were defined as follows: type I ALM have large round-oval nuclei with well-defined nuclear membrane, open and vesicular chromatin and distinct nucleoli and type II ALM have large oblong-spindle nuclei with irregular nuclear membrane/contour, dark-smudgy chromatin and pinpoint or obscure nucleoli. 51% ALM (27 of 53) were positive for 2SC, among which, 73% were type I (22 of 30) and 22% were type II (5 of 23) ALM. All control myometrium cases (n= 44) were negative for 2SC. Overall, 80% of type I ALM with 2SC expression displayed the typical SMT-FHs features. Re-review of type II 2SC-positive ALM (n= 5) showed that two of these cases had some SMT-FHs morphologic features. Mutational analysis showed that MED12and HMGA2 mutations skewed towards type II ALM (24% and 29% present, respectively) and were absent in type I ALM. Conclusions: ALM is can be readily divided into two different types based on the distinct histological features. A combined histologic and 2SC IHC approach can identify most, but not all, type I ALM as SMT-FHs tumors. Type I ALM are characterized by increased fumarate, whereas type II ALM may more frequently contain MED12 mutations and/or HMGA2 overexpression, suggesting a different mechanism of tumorigenesis. Julio Poveda, Carmen Gomez-Fernandez, Paula Espinal, Ernesto Martinez-Duarte, Elena Vrotsos, Pan Yue, Andre Pinto The current study aims to evaluate the demographic heterogeneity of these cancers, with special attention to serous carcinomas, on which published data is scant. Considering that similar molecular pathways may or may not reflect in some epidemiologic factors, we decided to analyze a cohort of high grade serous and basal-like breast carcinoma patients for comparison. Design: We performed a systematic review of our database of a 12-year period. A total of 65 ovarian HGSC and 40 TNBC, of possible basal-like subtype, were retrieved. The latter was tentatively achieved by eliminating all apocrine (and/or with positive androgen receptor immunostain) and lobular carcinomas, and including all medullary and metaplastic types. Due to limited sample size, we classified ethnicity and race into three groups: Hispanic Whites (HW), Non-Hispanic Whites (NHW) and Non-Hispanic African Americans (NHAA). Statistical analysis was implemented using SAS (SAS Institute, Version 9.1). Results: Of the 105 cases retrieved, 55 (52.4%) are HW, 28 (26.7%) are NHAA, and 22 (20.1%) are NHW. Chi-square tests were conducted and demonstrated significant ethnicity difference between the two cancers (p=0.0014). In our institution, the majority of HGSC patients are HW (66.2%), while the majority of BLBC patients are NHAA (37.5%). We further examined the ethnicity difference of demographics and risk behaviors and found no difference for age, BMI and age at menarche. The remaining analyzed factors (number of pregnancies, BRCA status, use of OCPs, history of hormone replacement therapy, smoking history) were not significant. Conclusions: Our results describe a significant ethnicity difference between BLBC and HGSC patients (p=0.0014), which paradoxically contrasts with the shared molecular equivalence among them. A study that includes a larger cohort is necessary in order to better comprehend this and the remaining associations (or lack thereof). A better understanding of the multifactor determinants of ovarian cancer may lead to the development of more effective screening programs. Many of these neoplasms have rhabdoid morphology (RM) and molecular abnormalities result in loss of immunostaining with INI1. Recently, SMARCA4 (BRG1), another member of the SWI/SNF pathway, important in the development of ovarian small cell carcinoma of hypercalcemic type, has been investigated in a small cohort of poorly differentiated endometrial adenocarcinomas. In that study, 24 cases of grade 3 endometrioid adenocarcinoma and 1 case of de-differentiated adenocarcinoma (DDC) (mixed endometrioid adenocarcinoma and undifferentiated carcinoma) were evaluated for BRG1 and INI1 expression. INI1 expression was intact in all cases but loss of BRG1 was identified in one case of DDC with RM. The aim of our study was to evaluate the expression of INI1 and BRG1 in a larger cohort of undifferentiated endometrial carcinomas (UCA). Design: Thirty-nine UCA (22 DDC and 17 pure UCA) were stained with BRG1 (n=39) and INI1 (n=27) on whole tissue sections. Both markers were assessed in tumor cells as intact (nuclear staining of any intensity) or lost (complete absence of nuclear staining). Loss of staining was considered only if there was a positive internal control (endothelial cells/stromal cells). Correlation of BRG1 and INI1 expression with clinical outcome was performed in 18 cases. Results: BRG1 was intact in 29 of 39 (74%) and lost in 10 of 39 (26%) cases. INI1 was intact in 26 of 27 (96%) cases. RM was present in 3 of 10 (30%) BRG1 negative cases; one case with INI1 loss did not have RM. In the BRG1 intact group, 7 of 13 (54%) patients died of disease (DOD), 5 (38%) were alive with no evidence of disease (ANED) and 1 (8%) was alive with disease at 33 months. In the BRG1 negative group, 2 of 5 (40%) were ANED, 2 (40%) DOD and 1 (20%) died of other causes. Conclusions: In our study, 26% of UCAs showed loss of BRG1 expression. Of these, only one-third was associated with RM. There was no correlation between BRG1 expression and outcome. Our preliminary data suggest that the SWI/SNF chromatin remodeling complex may be involved in the pathogenesis of UCA regardless of RM. Future studies should investigate the molecular changes underlying BRG1 loss. mucinous differentiation (n=2). All were FIGO grade 1 and stage I. Only 3 (23%) carcinomas were myoinvasive, but 1 case, a mucinous carcinoma, showed >50% myometrial invasion. Comparative analysis of the biopsies that preceded the carcinoma and the CMP group showed no significant differences regarding frequency of grade 2/3 atypia, mitotic index, extent of extracellular proliferation, presence of glands with mucin depletion, tissue volume, patient age and necrosis Conclusions: In sampling specimens, mucinous proliferations with features that are sub diagnostic of carcinoma represent a biologically-variable spectrum of lesions that includes mucinous hyperplastic proliferations, endometrioid and mucinous adenocarcinomas, and occasionally myoinvasive carcinomas. We did not identify any morphologic criteria predictive of the carcinoma subset of this group. Our findings suggest that there is a need for extra-morphologic tools to assist in predicting which mucinous proliferations are most likely to be associated with malignancy.
Fumarate Hydratase Alteration and Other Molecular Changes in Two Histologic Variants of Atypical Leiomyomas
Epidemiologic Dissociation between Two Subtypes of Molecularly Similar Tumors
Loss of Expression of SMARCA4 (BRG1) and SMARCB1 (INI1) in
Expression of PD-L1 in Ovarian Tumors May Provide Potential Immunotherapy Candidates
Opal L Reddy, Itsushi P Shintaku, Neda A Moatamed. David Geffen School of Medicine at UCLA, Los Angeles, CA. Background: Programmed death ligand 1(PD-L1) is a transmembrane protein involved in immune responses. The interaction of PD-L1 with its receptor PD-1 on T cells has been shown to block anti-tumor T-cell function. Tumor expression of PD-L1 has facilitated the development of immune therapies to treat malignancies such as melanoma and some lung carcinomas. This study is the first systematic evaluation of PD-L1 expression in ovarian neoplasms. Design: We assessed PD-L1 expression on a tissue microarray of 227 normal and neoplastic ovarian tissues. Immunohistochemical staining of the tissues was carried out using anti-PD-L1 (rabbit monoclonal, clone SP142) antibody. Absent cell membrane staining of PD-L1 was scored as negative and present staining was scored as positive. Results: Table 1 summarizes the frequency of PD-L1 positivity in ovarian tissues. Overall, PD-L1 was positive in 31% (54/174) of all ovarian malignancies. Subcategorically, 48% (22/46) of serous, 38% (3/8) of clear cell, 37% (15/41) of endometrioid, 33% (1/3) of undifferentiated, 6% (1/18) of mucinous, and 7% (1/14) of metastatic carcinomas were positive. PD-L1 was also positive in 50% of germ cell tumors (10/20). All borderline and benign tumors as well as the normal ovary were negative for PD-L1 expression. Background: Programmed cell death ligand 1 (PD-L1) is a transmembrane protein involved in the regulation of immune responses. PD-L1 by binding to its receptor PD-1 on the T cells, provides signals in regulating T cell activation and blocking anti-tumor immunity. The PD-1/PD-L1 axis has emerged as a promising new target for cancer therapeutics that has induced lasting responses in the treatment of metastatic renal and lung carcinomas, as well as melanomas. In this study, we investigated the expression of PD-L1 in human cervical tissue and cervical tumors. Design: Immunohistochemistry was used to assess PD-L1 expression on a tissue microarray of 100 normal and neoplastic cervical tissues. Hematoxylin & eosin and PD-L1 immunohistochemical staining (clone SP142, rabbit monoclonal antibody) were performed. PD-L1 expression was scored as positive when present on cell membranes (Figure 1 ), regardless of cell numbers, and negative when absent.
Results: Table 1 summarizes the frequency of PD-L1 positivity in 100 cervical tissues. Overall, PD-L1 was positive in 72% (68/94) of cervical malignancies. Sub-categorically, 78% (57/73) of squamous cell carcinomas, 58% (7/12) of endocervical carcinomas, 43% (3/7) of adenosquamous carcinomas, and 100% (1/1) of small cell carcinomas were positive for PD-L1. It was negative in one endometrial carcinoma, benign lesions, and normal cervical tissues. Conclusions: This study shows significant expression of PD-L1 in 78% of the cervical malignancies, suggesting a role for future investigation of anti-PD-L1/PD-1 immunotherapies in the treatment of PD-L1-positive cervical tumors. Conclusions: Expression of AR shows a significant positive correlation with ER and PR. AR expression might be useful as a good prognostic indicator in EC.
Incidence of Occult Carcinomas in Fallopian Tubes in High-risk Patients -A Prospective Study from North Shore -LIJ Health System
Sudarshana Roychoudhury, Peter Farmer, Cathy Fan, Sharon Liang. Hofstra North Shore -LIJ Health System, Lake Success, NY. Background: Fallopian tubes harbor occult serous carcinomas in many risk-reducing salpingo-oophorectomy specimens (RRSO), a preventive measure to reduce ovarian carcinomas in patients with high-risk factors including germline BRCA1/2 mutations or hereditary breast ovarian cancer syndrome (HBOC). The purpose of this study was to determine the incidence of occult malignancies in the fimbria with or without risk factors. Design: 187 surgical specimens were collected from January 2012 to September 2015, and processed following the standard SEE-FIM protocol. Ninety-four patients underwent RRSO and 93 bilateral salpingo-oophorectomy (BSO with/without hysterectomy) for other gynecologic conditions. Patients' demographics and significant histopathologic findings of the fallopian tubes were recorded. Results: Four (4.3%) of 94 RRSO had occult non-invasive serous carcinoma in the fimbria (1-5 mm), while none were identified in BSO group (p=0.044). All these 4 patients (3 BRCA1, 1 BRCA2) were asymptomatic with normal CA-125. Three were stage 1A and 1 stage 3B (treated with chemotherapy). All four patients were alive without disease during 6 to 36 month follow-up. Another 60 y.o patient (BRCA1) with negative findings in RRSO had peritoneal serous carcinoma 26 months later. She received chemotherapy and currently is disease free. In addition, serous tubal intraepithelial carcinoma (STIC) was identified in 2 RRSO, both associated with occult carcinoma. Two BSO had incidental STIC. One patient with BRCA1 mutation had p53 signature. Other benign epithelial changes (adenofibroma and mucinous metaplaisa) were also noted in RRSO group (6 and 5) and BSO group (5 and 2). Three of 5 mucinous metaplasia in RRSO were seen in patients with breast carcinoma.
Conclusions:
The incidence of occult carcinomas in fallopian tubes was 4.3% in high-risk group in this cohort, which is comparable with reported incidence. Risk of peritoneal carcinomas after RRSO remains. None of 12 patients with HBOC syndrome had occult malignancies, raising a question of whether family history alone without BRCA status is justifiable to receive RRSO.
group reclassified as HSIL (p<0.001). p16 was positive in 245/507 patients (48.3%) and in 210/416 patients (50.5%) with confirmed LSIL at reevaluation. Although in the overall group of patients with LSIL a positive p16 immunostaining was associated with risk of progression in the multivariate analysis (Hazard ratio (HR) 1.9;95% confidence interval (CI): 1.2-3.1; p=0.009), this association was not verified in the subset of patients with confirmed LSIL at reevaluation (HR: 1.6;95% CI:0.9-2.6;p=0.095). Conclusions: p16 usefulness in LSIL lesions should be limited to equivocal cases in which HSIL is included in the differential diagnosis and has low value in clinical practice as a marker of progression of LSIL. This work was partly supported by Instituto de Salud Carlos III-Fondos de Investigacion Sanitaria and ERDF (PI12/01231 and PI12/01165).
lymphocytes (TILs) (0, none; 1, 1-25%; 2, 25-50%; 3, >50%), and the presence of a Crohn's like response (CLR). IHC was performed for PD-L1 (E1L3N, Cell Signaling), CD3, CD20, and CD163. PD-L1 was assessed in the tumor compartment and in the inflammatory compartment. PD-L1 was considered positive if membranous staining was observed in ≥1% of tumor cells or ≥ 1% of total inflammatory cells. Results: 76 ASEC patients were identified. Of these, 22 (29%) were endometrioid grade 1 or 2, 17 (22%) were endometrioid grade 3, and 37 (49%) were serous. As defined, PD-L1 expression was negative in all tumors; PD-L1 expression in <1% of tumor cells was seen in 4 cases, but this did not seem to correlate with morphologic factors. PD-L1 was positive in the inflammatory compartment (1-3% of cells) in 3 separate cases from those with focal tumor staining; all 3 tumors exhibited a CLR and had a TIL score of 1. In 28 (37%)tumors, PD-L1 was noted to stain a substantial proportion of tumor infiltrating macrophages, but did not reach the 1% threshold for positivity when all inflammatory cells were combined.
The utility of predictive biomarkers for immunotherapy response remains unproven in ASEC. PD-L1 immunopositivity, as defined by thresholds studied in other tumor types, is uncommon in otherwise unselected ASEC. Staining of tumor macrophages with PD-L1 may warrant further investigation. Because other biomarkers such as microsatellite instability and mutation burden have also shown promise in predicting response to immunotherapy in other tumor types, further study of PD-L1 in ASEC enriched for these phenotypes may be useful. (13/15; 87%). Staining for Arg1 was uniformly negative except for one metastatic HCC. Conventional YSTs were uniformly positive for albumin, AFP, and Gly-3, and negative for Arg1. Among ovarian serous carcinomas, 22/360 were positive for Gly3 (6%) and only 2/360 for AFP (< 1%); all were negative for albumin and Arg1. Among 66 ovarian endometrioid carcinomas, 1 was positive for albumin (1.5% The chemotherapy response score (CRS) stratifies tubo-ovarian highgrade serous carcinoma (HGSC) patients into different prognostic groups as determined by progression-free and overall survival, providing opportunities for early treatment modulation. CRS is assessed on omental sections from interval debulking surgery specimens after neo-adjuvant chemotherapy for HGSC.
CRS Criteria 1
Mainly viable tumour with minimal regression limited to a few foci
2
Multifocal or diffuse regression ranging from viable tumour in sheets, streaks or nodules, to extensive regression with multifocal residual tumour which is easily identifiable.
3
Complete or near-complete response with no residual tumour OR minimal irregularly scattered tumour foci seen as individual cells, cell groups or nodules up to 2mm in maximum size
We sought to determine inter-observer agreement in CRS assignment. Design: After online training (http://www.gpecimage.ubc.ca/aperio/images/crs), all omental sections (4-10 slides) from 40 cases were scored independently by 15 study pathologists, 3 from each of 5 categories: original study pathologists, junior trainees, senior trainees, new consultants (<2 years since appointment) and experienced gynecological pathologists (>15 years' specialist experience). Interobserver agreement was assessed within and between groups. Results: Kappa scores, Kendall's coefficient of concordance and absolute agreement for the different groups and overall are shown below. Mucinous differentiation was present in 50% of cases (10/20). TILs were present in 60% (12/20) of SMECs, and in 90% (9/10) of those with mucinous differentiation. A subset of LS-associated ECs showed biphasic/de-differentiation (23%, 6/26) and TILs (23%, 6/26), but mucinous differentiation was rare (4%, 1/26). The majority of SMECs presented at a low stage (85%, 17/20 Background: It is believed that teratomas are of germ cell origin and often demonstrate partial or complete homozygosity -a phenomenon rare in neoplasia and supportive of the theory of their origin from a germ cell that has undergone the first meiotic division. Although homozygosity is well documented in mature teratomas, the genetic zygosity of immature teratomas is less well studied. Design: Ten cases of mature ovarian teratomas and seventeen cases of immature ovarian teratomas were retrieved from our departmental archives and reviewed. Target tumor tissue and paired nonneoplastic normal tissue were microscopically dissected for short tandem repeat (STR) genotyping.
Results: All mature teratomas were classic mature cystic teratomas with the patients' age ranging from 16 to 67 years. Immature teratomas had an age range from 9 to 48 years and tumor grade ranging from G1 to G3. Six of the immature teratomas contained additional tumor types including yolk sac, clear cell carcinoma, embryonal, and choriocarcinoma. Of the mature teratomas, 5 cases showed partial or complete homozygosity (63%) with 2 cases demonstrating complete homozygosity (25%) ( Table  1) . Of the immature teratomas, 9 cases showed partial or complete homozygosity (75%) with 2 cases demonstrating complete homozygosity (17% Background: Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the pleural cavity and less commonly in other body cavities including the peritoneum. Most pleural mesotheliomas arise in patients with a history of asbestos exposure, whereas peritoneal mesotheliomas do not have well described carcinogens or risk factors. Genomic analysis has defined the spectrum of molecular alterations that drive pleural mesothelioma including CDKN2A deletion (>50% of cases), NF2 mutation (∼40% of cases), and BAP1 mutation (~30% of cases). In contrast, the recurrent genetic alterations which drive peritoneal mesotheliomas remain unidentified. Design: Targeted next-generation sequencing of >500 cancer-associated genes was performed on 9 malignant peritoneal mesotheliomas and matched normal tissue. Average read depth was approximately 500x. Immunohistochemistry for BAP1 was performed on these 9 malignant peritoneal mesotheliomas, 7 well-differentiated papillary mesotheliomas (WDPM) of the peritoneum, and 12 peritoneal metastases of low grade serous carcinoma of the ovary (LGSCO). Results: Somatic biallelic inactivating mutations or homozygous deletions of the BAP1 gene on chromosome 3p were identified in 7 of the 9 malignant peritoneal mesotheliomas. Loss of nuclear staining for BAP1 protein was seen in each of these seven malignant peritoneal mesotheliomas and in no WDPM of the peritoneum or peritoneal metastases of LGSCO. In all cases with BAP1 loss, retained expression was present in non-neoplastic stromal and endothelial cells. Conclusions: These studies identify inactivating mutations of BAP1 as the most frequent genetic alteration in peritoneal mesotheliomas identified to date and suggest that BAP1-mediated transcriptional deregulation is a key oncogenic mechanism in mesothelial tumorigenesis. The resulting loss of BAP1 nuclear expression is a helpful biomarker for the pathologic identification of malignant peritoneal mesotheliomas, as intact BAP1 expression was seen in all cases of potential histologic mimics such as WDPM and peritoneal metastases of LGSCO. Epithelioid morphology was the second most common finding (14 cases), accompanied by <5MF/10HPF and/or cytological atypia. Six neoplasms had myxoid features accompanied by mitosis of <2MF/10HPF in all cases and focal severe atypia in 2. 9 patients (20%) developed recurrent disease at 12 to 90 months (mean 38). 5 had epithelioid histology accompanied by necrosis of uncertain type in 3 cases (1 also with diffuse severe atypia), diffuse severe atypia in 1 case and <5MF/10HPF with increased cellularity in one case. 3 had diffuse severe atypia and 5-9MF/10HPF. One had increased cellularity and severe atypia. One patient developed intrauterine recurrence at 20 months following myomectomy. Two patients developed pelvic recurrences at 24 and 43 months; 4 developed abdominal recurrences at 12, 17, 25, and 90 months; and two developed lung metastasis at 28 and 84 months. One had a second abdominal recurrence at 34 months. Eight of nine patients had history of either morcellation or myomectomy at the time of initial diagnosis. No patient succumbed to disease in the follow up period. Conclusions: STUMPs may recur in the pelvis, abdomen, or lungs, particularly following morcellation. STUMP with epithelioid histology accompanied by either atypia or necrosis of uncertain type is the most common STUMP to recur. As most recurrent STUMPs in this series were associated with previous morcellation, seeding secondary to abdominal spillage cannot be excluded. [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] to retrospectively identify APs. Cases with available material were evaluated for the following morphologic features: stromal cellularity, pattern of myomatous features (type 1: vaguely fascicular myomatous stroma intimately admixed with glands; type 2: well-defined fascicles with a hamartomatous appearance, predominantly in the stalk of the polyp but also entrapping glands). Immunohistochemistry (IHC) for CD10, desmin, and caldesmon was performed. Clinical data was obtained from the medical record. For cases seen in consultation, the referring pathologists' favored diagnoses were recorded. Results: APs were seen in consultation ~10 times per year (2007-2015, n=76 ) and were associated with a broad differential diagnosis that included adenosarcoma (13), endometrial neoplasia/carcinoma (7), endometrial stromal tumor (6) and atypical polypoid adenomyoma (4). The in-house cohort included 89 patients (age 27 to 89 years, mean 51 years) with histologically-confirmed APs (average size 2.4 cm, range 0.4 to 10.2 cm). 58% (52/89) presented with abnormal uterine bleeding, and, clinically, 22% (20/89) of polyps were thought to represent submucosal leiomyomas. By H&E review, we identified 51 type 1 APs, 34 type 2 APs, and 4 polyps with mixed features. For cases with tissue blocks available, CD10 was positive at least focally in all specimens examined (n=77), and 91% (70/77) stained strongly positive for desmin. Of type 2 APs, 97% (28/29) were positive for caldesmon while only 6.8% (3/44) of type 1 APs had more than focal caldesmon positivity. A subset of type 1 APs (11%, 5/44) were desmin negative. Conclusions: This study represents the first comprehensive clinicopathologic and immunohistochemical characterization of adenomyomatous polyps. They are not uncommon in routine diagnostic practice and may be misinterpreted as a more worrisome lesion. The majority of patients with APs present with abnormal uterine bleeding, and APs can be mistaken for submucosal leiomyomas on ultrasound or hysteroscopic examination. The lack of caldesmon positivity suggests that a subset of cases classified as adenomyomatous on H&E may represent endometrial polyps with cellular endometrial stroma. The human epidermal growth factor (HER) receptor family is extensively involved in carcinogenesis. While the prognostic impact of HER1 (EGFR) and HER2/ neu has been characterized in numerous cancers, there is little data on the role and prognostic/predictive impact of HER4 in ovarian cancer. Design: Levels of HER4 expression were evaluated in a tumor microarray (TMA) consisting of 177 tissue samples including 100 ovarian serous carcinoma (OSC) specimens (50 complete responders (CR) and 50 incomplete responders (IR) to platinum-based chemotherapy), 51 tissue samples from normal, non-neoplastic ovarian and fallopian tube control, and 16 platinum resistant cell lines (PRCL). Levels were scored by "H"-score. Expression scores were arbitrarily classified into 'low' (0-100), 'intermediate' (101-200) and 'high' (201-300) categories. Category frequencies were compared between tumor specimens versus controls using chi-square methodology. Among tumors, category frequencies were compared between CR and IR to chemotherapy; and overall survival (OS) was stratified by category and compared using Kaplan-Meier methodology.
HER4 Expression and Overall Survival in Ovarian Serous
Results: In total, 74 OSC (32 CR and 42 IR), 28 normal control and 16 PRCL specimens were evaluable. The medium years of age at diagnosis was 62. High-level HER4 cytoplasmic and nuclear expression (201-300) was observed at a significantly higher frequency in OSC versus normal tissue controls, whereas low-level expression (0-100) was seen at significantly higher frequency in control specimens (p=0.001). Among tumor specimens, HER4 expression was significantly higher in patients with IR to chemotherapy versus CR (p=0.04 
Results:
The age at onset ranges from 36 to 64 years old, with an average of 51.2 years old. All patients presents with advanced stage at onset (>/= stage 3a). Histologically the tumor shows abrupt transition from well-differentiated endometrioid carcinoma to completely undifferentiated carcinoma. The amount of undifferentiated component ranges 25-70%. Tumor involvement of lower uterine segment, lymph node metastasis, and lymphovascular invasion are frequently found. 3 of 5 cases demonstrate MSI, all with loss of MLH1 and PMS2, secondary to hypermethylation of MLH1 (sporadic MSI).
Comparison of IHC results of undifferentiated to those of differentiated component reveals: 1) frequent loss of epithelial markers; 2) loss of lineage specific markers PAX 8 and ER/PR; 3) stronger p53, c-Myc, Cyclin D1 and CD117 expression; 4) higher proliferation index; 5) partial loss of cell adhesion protein E-cadherin.
Conclusions:
The unique features of DEMC, such as advanced stage at presentation, aggressive clinical behavior and frequent association with MSI are confirmed. In our study, MSI is due to hypermethylation (sporadic) in all 3 cases. Undifferentiated component demonstrates loss of epithelial and lineage specific markers, progressive gaining of genetic abnormalities, high proliferation rate, and partial loss of cell adhesion molecule E-cadherin, which may be associated with epithelial-mesenchymal transition.
False Negative Endometrial Sampling in Patients with Endometrial Carcinoma
Catalin Taraboanta, Heidi Britton, Blake Gilks. University of British Columbia, Vancouver, BC, Canada. Background: Endometrial cancer is the most common gynecological, and the fourth most common cancer in women. Outpatient endometrial sampling is highly accurate in diagnosing endometrial cancer, if an adequate sample is obtained. A negative result however is less reassuring with a post-test probability for endometrial cancer of 0.9% (95% CI: 0.4% -2.4%). Our goal was to determine: false negative rate and sensitivity of endometrial sampling in patients with endometrial carcinoma from our region. Design: In a retrospective cross-sectional design, we identified all hysterectomies with pathology reported between February 2013 and May 2015 in our regional anatomical pathology data base, by querying the terms "carcinoma", "adenocarcinoma" or "hyperplasia" in the final diagnosis. Cases of primary ovarian, cervical, or fallopian tube carcinoma, metastatic carcinomas, outside consultations and cases with no endometrial sampling were excluded. The cases identified were then cross-referenced with patient's endometrial sampling results, reported up to five years prior to hysterectomy. We defined negative endometrial samples as either benign or non-diagnostic, excluding cases of atypical hyperplasia and those where follow-up sampling was recommended. Results: We reviewed 1,330 pathology reports and identified 931 cases of hysterectomy for endometrial carcinoma or atypical hyperplasia. In 119 cases there was a previous negative biopsy: 92 benign and 27 non-diagnostic. Out of these, 98 (82%) cases were diagnosed as endometrioid adenocarcinoma, 6 (0.5%) serous carcinoma, and 13 (10%) atypical hyperplasia on the hysterectomy specimen. The median time between negative biopsy and hysterectomy was 163 days (IQR: 84 -547) and FIGO stage was 1 in 67%, 2 in 23% and 3 in 10% of carcinoma cases. A total of 11,787 negative endometrial biopsies were reported in our region between February 2013 and May 2015. The false negative rate (miss rate) was 12.7% for carcinoma or atypical hyperplasia. Calculated sensitivity was 87.2% with a post-test probability of endometrial cancer, given a negative endometrial sample, of 1.0%. Conclusions: Our findings are comparable with those published more than a decade ago. There remains a significant lack of sensitivity with outpatient endometrial sampling in the diagnosis of endometrial malignancy and pre-malignancy; both pathologists and primary care physicians should be aware of this. Results: 896 women were tested, of which 67% were HPV DNA positive. Clinical sensitivity and specificity for detection of CIN2+ was 89.5% and 54.3% for the Cobas test and 88.5% and 60.0% for the Aptima test in women referred with minor abnormalities (n =300). We also applied the data to model the potential to reduce colposcopy referral rate following HPV DNA/ mRNA testing and triage of HPV positive cases with HPV16/18 genotyping or cytology. In HPV positive women, the sensitivity for detecting CIN2+ remains high and the referral rate would drop to 60% of the overall population indicating a potential reduction of 40% in referrals. Where HPV positive women had a cytology test applied, the referral rate would drop to 38%, the sensitivity for detecting CIN2+ remains high. HPV 16/18 genotyping could reduce the referral rate by a similar proportion, however, the sensitivity was considerably lower which could result in delayed diagnosis of CIN2+. CINtec PLUS data is currently under review.
Conclusions:
The specificity of HPV testing can be improved by including additional biomarkers as tests of disease. Background: Upon detection of the precursor of adenocarcinoma of the cervix, adenocarcinoma in situ (AIS), hysterectomy with routine surveillance is considered the definitive treatment. However, conclusive management may be problematic, particularly in women who wish to maintain fertility. Hence, select patients may be treated conservatively. Thus far, the leading factor demonstrated in predicting subsequent disease is the status of the excisional margin. Further pathologic factors that may identify patients appropriate for conservative management remain undefined. The present study aims to determine the outcomes of women with AIS, to establish the impact of an expanded set of pathologic parameters detectible at cervical conization. Design: A retrospective review of cases of AIS diagnosed in a cervical conization from 2000 to 2014 was conducted. Clinical, pathologic and temporal variables were collected for the excisions, hysterectomies and post-operative surveillance.
Results: Fifty patients with AIS were identified. The mean age at diagnosis was 37 (range 17-76 yrs). Nineteen patients (38%) underwent hysterectomy. In the hysterectomies, there was one case of adenocarcinoma, residual AIS was noted in 5 patients (26%) and 13 (68%) were free of residual disease. The remaining 31 women (62%) were treated conservatively. Of these, one showed adenocarcinoma in a subsequent excisional specimen and all were free of disease at last contact; average length of follow-up was 61.1 months (range 3-172). Patients with residual AIS or adenocarcinoma were significantly older than those without residual/progressive disease (48.7 vs. 35.3, p=0.0010). A significant difference was not found between those with AIS/progressive disease and those free of disease in regards to associated squamous dysplasia, disease extent (quadrants/sections involved, horizontal/vertical extension, multifocality), or the qualitative/quantitative status of the margins (direct/close involvement, distance to margins) in either the entire cohort or hysterectomy group alone. Conclusions: These results suggest that following a cervical excisional procedure, conservative management with routine surveillance may be an acceptable approach in the management of AIS. Older age at diagnosis may pose an increased risk for residual or progressive disease. Evaluation of pathologic parameters related to the burden of disease and margin does not appear to correlate with the presence of residual/persistent AIS or disease progression. Background: Atypical endometrial hyperplasia is thought to represent a direct precursor to endometrioid adenocarcinoma of the uterine corpus. Next generation sequencing (NGS) on endometrioid carcinoma and associated endometrial hyperplasia has not been reported to our knowledge. We thus set out to perform NGS on a case of endometrioid adenocarcinoma and associated atypical hyperplasia, to investigate genetic commonality between these processes. Design: A simple hysterectomy case was identified that contained endometrioid adenocarcinoma and morphologically distinct atypical endometrial hyperplasia. Areas of atypical hyperplasia and endometrioid adenocarcinoma were macrodissected from formalin fixed paraffin embedded tissue. Normal ovary was macrodissected as germline material. DNA was extracted using Quagen extraction kits. NGS was performed on the three specimens using the Ion Proton Instrument (Life Technologies) and the Ion Ampliseq Comprehensive Cancer Panel, which targets the coding regions of 409 cancer-associated genes. Variants were called in carcinoma and atypical hyperplasia samples using the ovarian DNA as normal germline. Called variants were filtered using a standard set of parameters.
OTUB1 Exhibts a Subtype-Specific Expression and Predicts Poor Prognosis by Promoting Tumor Progression in Ovarian Epithelial
Results:
The endometrioid adenocarcinoma and endometrial hyperplasia samples harbored identical somatic mutations in three genes commonly mutated in endometrioid adenocarcinoma: PIK3CA (p.Arg88Gln), PTEN (p.Arg130Gly; p.Ala121fs), and KMT2D (p.Leu4214Ter). Identical mutations in BCL9 (p.His1122Pro) were also identified in hyperplasia and carcinoma. The endometrioid adenocarcinoma harbored mutations not present in the atypical hyperplasia. These included ARID1A (p.Arg2158Ter) and CTNNB1 (p.Ser33Tyr), genes commonly mutated in endometrioid adenocarcinoma.
Conclusions:
The findings in this study corroborate that atypical endometrial hyperplasia is a direct precursor to endometrioid adenocarcinoma, as several identical mutations in this case were present in both hyperplasia and carcinoma. That ARID1A and CTNNB1 were present in the carcinoma, but not in the hyperplasia, suggests these may be involved in progression from atypical hyperplasia to fully-developed endometrioid adenocarcinoma.
